




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 233/55, C07D 213/79		A1	(11) International Publication Number: WO 99/07669 (43) International Publication Date: 18 February 1999 (18.02.99)
(21) International Application Number: PCT/US98/16099		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 3 August 1998 (03.08.98)			
(30) Priority Data: 08/906,683 5 August 1997 (05.08.97) US			
(71) Applicant: AMERICAN HOME PRODUCTS CORPORATION [US/US]; Five Giralda Farms, Madison, NJ 07940-0874 (US).			
(72) Inventors: LENNOX, Joseph, Richard; 2128 Arbor View Drive, Morrisville, NC 27560 (US). ANTANE, Schuyler, Adam; 14214 Marie Court, Lawrenceville, NJ 08648 (US). BUTERA, John, Anthony; 6 Lawrence Spring Drive, Clarksburg, NJ 08510 (US).		Published <i>With international search report.</i>	
(74) Agents: ALICE, Ronald, W.; American Home Products Corporation, Patent Law Dept. - 2B, One Campus Drive, Parsippany, NJ 07054 (US) et al.			

(54) Title: ANTHRANILIC ACID ANALOGS

(57) Abstract



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

Anthranilic Acid Analogs

Background of Invention

5

The present invention relates to a novel series of anthranilic acid-derived amides (I) having pharmacological activity, to a process for their preparation, to pharmaceutical compositions containing them, and to their use in the treatment of disorders associated with smooth muscle contraction, via potassium channel and chloride channel modulation. Such disorders include, but are not limited to: urinary incontinence, asthma, premature labor, irritable bowel syndrome, congestive heart failure, angina, and cerebral vascular disease.

Modulation of potassium channels remains at the forefront of current approaches for controlling resting cell membrane potential and affecting cell excitability. A wide variety of discrete potassium channels exist and these have been thoroughly classified according to structure, function, pharmacological properties, and gating mechanisms in several recent reviews [Rudy, B. *Neuroscience* **1988**, *25*, 729-749; Atwal, K., *Medicinal Research Reviews* **1992**, *12*, 569-591; Gopalakrishnan, M. et al., *Drug Development Research* **1993**, *28*, 95-127; Primeau, J. et al. *Current Pharmaceutical Design* **1995**, *1*, 391-406; Edwards, G. et al. *Exp. Opin. Invest. Drugs* **1996**, *5* (11), 1453-1464]. Therapeutic potential for potassium channel modulators in cardiovascular disorders, metabolic disorders, central nervous system disorders, bronchial asthma, and irritable bladder is being vastly explored.

25

Research interests in the modulation of chloride channels are growing at a fast pace [Strange, K. et al. *Kidney International* 1995, 48, 994-1003; Franciolini, F. et al. *Biochimica et Biophysica Acta* 1990, 247]. Various disease states potentially amenable to chloride channel modulation include bronchial asthma, cardiac arrhythmias, cystic fibrosis, and kidney disease.

Harita et al. disclose a process for the manufacturing of a class of *meta*-substituted aromatic amide carboxylic acid derivatives in Japanese Patent Application No. 49-102692, and also builds on a method for manufacturing aromatic cinammic acid derivatives in Japanese Patent Application No. 49-42465. Several patents and patent 5 applications focus particularly on agents possessing claims of anti-allergic /anti-asthmatic/anti-histaminic activity: Sato et al. report a group of anthranilic acid derivatives (highlighting Tranilast® as an anti-allergic-agent) in Japanese Patent Application No. 57-179976; related to these anthranilates is a claim by Aoyanagi et. al. in Japanese Patent Application No. 58-79436 which discloses a method for 10 manufacturing anthranilic acid derivatives; also related is Hungarian Patent HU 200 996 B which emphasizes the production of several Tranilast® analogs; and Yukihiko, in Japanese Patent No. J6 0019-754-A, has also indicated a method for the preparation of anthranilic acid derivatives where the styrenyl portion is strictly limited to alkoxy, hydroxy or acyloxy.

15

In addition, Japanese Patent No. J0 2218-654-A by Tsumoro et al. which reveals a class of amino-benzoic acid derivatives which are useful as reverse transcriptase inhibitors. Also by Tsumoro et al., Patent No. J6 0097-946-A discloses a series of substituted carboxamide derivatives which exhibit activity as leucotriene 20 antagonists and phospholipase inhibitors.

Brief Description of the Figures


25 **Figure 1** is a schematic representation of a single cell recordings of cell current. Figure 1A shows cell outward current of the control. Figure 1B shows cell outward current following exposure of cells to compound of Example 1. Figure 1C shows cell outward current following washout.

30 **Figure 2** is a schematic representation of the effects of Example 1 on chloride channel current induced by swelling. Figure 2A depicts current traces for a cell in isotonic, low osmolarity and after exposure to Example 1. Figure 2B depicts voltage dependency of current recorded in the presence of control (C), hypotonic (swelling), Example 1(WY) and washout solutions (washout). Figure 2C depicts the time course of the effect on Example 1 on chloride channel current.

- 3 -

Description of The Invention

In accordance with the present invention, there is provided compounds represented by the formula:



5

(I)

wherein:

10 $R_1, R_2, R_3, R_4, R_5, R_6, R_7$ and R_8 are, independently, hydrogen, $COOR_{15}$, halogen, nitro, cyano, C_{1-10} alkoxy, C_{1-10} haloalkoxy, sulfonic acid, C_{1-10} alkylsulfonyl, C_{6-12} arylsulfonyl, C_{6-12} aralkylsulfonyl, C_{1-10} alkylsulfinyl, C_{6-12} arylsulfinyl, C_{6-12} aralkylsulfinyl, sulfamoyl, C_{1-10} alkylsulfamido, C_{6-12} arylsulfamido, C_{1-10} alkanoyl, C_{6-12} aryloyl, C_{6-12} aralkanoyl, amino, C_{1-10} alkylamino, C_{2-10} dialkylamino, C_{6-12} aralkylamino, C_{6-12} arylamino, carboxamido, C_{1-10} alkylcarboxamido, C_{6-12} arylcarboxamido, C_{1-10} haloalkyl, C_{1-10} alkyl, C_{2-12} alkenyl, C_{6-12} aryl, C_{6-12} aralkyl; with the proviso that at least one of R_4 and R_5 is $COOR_{15}$;

15 R_9 is hydrogen, C_{1-10} alkyl and C_{1-10} haloalkyl;

20 R_{10} is hydrogen, C_{1-10} alkyl, C_{1-10} haloalkyl, or C_{2-12} alkylidene; R_{15} is hydrogen, metal cation, acetyl amido, alkoxyacetoyl or a related moiety which delivers the carboxylate in vivo; the dotted line is an optional double bond; with the proviso that when R_{10} is an alkylidene moiety, the bond is absent; and

25 W is nitrogen or carbon bearing a hydrogen, or R_4 , R_5 or R_6 as hereinbefore defined; or pharmaceutical salts thereof.

- 4 -

In some preferred embodiments R_1 , R_2 and R_3 are, independently, hydrogen, cyano, C_{1-10} perhaloalkoxy, sulfonic acid, C_{1-10} alkylsulfonyl, C_{6-12} arylsulfonyl, C_{6-12} aralkylsulfonyl, C_{1-10} alkylsulfinyl, C_{6-12} arylsufinyl, C_{6-12} aralkylsufinyl, sulfamoyl, C_{1-10} alkylsulfamido, C_{6-12} arylsulfamido, C_{1-10} alkanoyl, C_{6-12} aryloyl, C_{6-12} aralkanoyl, amino, C_{1-10} alkylamino, C_{2-10} dialkylamino, C_{6-12} aralkylamino, C_{6-12} arylamino, carboxamido, C_{1-10} alkylcarboxamido, C_{6-12} arylcarboxamido, C_{1-10} perhaloalkyl; with the provisos: (1) that R_1 , R_2 and R_3 may not all simultaneously be hydrogen, and (2) when R_1 and R_2 are hydrogen, R_3 may not be *meta*- CF_3 ;

R_4 , R_5 , R_6 , R_7 and R_8 are, independently, hydrogen, $COOR_{15}$, halogen, nitro, cyano, C_{1-10} alkoxy, C_{1-10} haloalkoxy, sulfonic acid, C_{1-10} alkylsulfonyl, C_{6-12} arylsulfonyl, C_{6-12} aralkylsulfonyl, C_{1-10} alkylsulfinyl, C_{6-12} arylsufinyl, C_{6-12} aralkylsufinyl, sulfamoyl, C_{1-10} alkylsulfamido, C_{6-12} arylsulfamido, C_{1-10} alkanoyl, C_{6-12} aryloyl, C_{6-12} aralkanoyl, amino, C_{1-10} alkylamino, C_{2-10} dialkylamino, C_{6-12} aralkylamino, C_{6-12} arylamino, carboxamido, C_{1-10} alkylcarboxamido, C_{6-12} arylcarboxamido, C_{1-10} haloalkyl, C_{1-10} alkyl, C_{2-10} alkenyl, C_{6-12} aryl, and C_{6-12} aralkyl, with the proviso that at least one of R_4 and R_5 is $COOR_{15}$;

R_9 is hydrogen, C_{1-10} alkyl and C_{1-10} haloalkyl;

R_{10} is hydrogen, C_{1-10} alkyl, C_{1-10} haloalkyl, or C_{2-12} alkylidene;

R_{15} is hydrogen, metal cation, acetyl amido, alkoxyacetoyl or a related moiety which delivers the carboxylate in vivo;

the dotted line is an optional double bond; with the proviso that when R_{10} is an alkylidene moiety, the bond is absent; and

W is nitrogen or carbon bearing a hydrogen, or R_4 , R_5 or R_6 as hereinbefore defined; or pharmaceutical salts thereof.

In other preferred aspects of this invention R_{15} is selected from the group consisting of hydrogen, a metal cation, a moiety selected from:



30 wherein R_{11} , R_{12} , R_{13} , and R_{14} are, independently, hydrogen, C_{1-10} alkyl, C_{6-12} aryl, or C_{6-12} aralkyl.

- 5 -

In still other preferred embodiments of the present invention, W is nitrogen, or a carbon bearing one of hydrogen, halogen, nitro, cyano, or C_{1-10} haloalkyl. More preferably W is carbon bearing a hydrogen.

5

In some aspects of the invention it is preferred that R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 and R_8 are, independently, selected from hydrogen, halogen, $COOR_{15}$, nitro, cyano, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} haloalkoxy, C_{6-10} aryloyl, C_{1-6} alkylsulfonyl, C_{1-6} haloalkylsulfonyl, C_{6-10} arylsulfonyl, C_{1-6} haloalkyl, C_{1-6} alkyl, amino, and C_{1-6} dialkylamino, with the provisos that (1) R_1 , R_2 and R_3 may not simultaneously be hydrogen, (2) when R_1 and R_2 are hydrogen, R_3 is not *meta*- CF_3 , and (3) at least one of R_4 and R_5 is $COOR_{15}$.

15 It is also preferred in some aspects of the invention that R_1 , R_2 and R_3 are selected from hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, nitro, C_{1-6} dialkylamino and halogen with the provisos that (1) R_1 , R_2 and R_3 may not simultaneously be hydrogen and (2) when R_1 and R_2 are hydrogen, R_3 is not *meta*- CF_3 . With the foregoing provisos, it is further preferred that at least one of R_1 , R_2 and R_3 is perhaloalkyl more preferably trifluoromethyl. Where one of R_1 , R_2 and R_3 is perhaloalkyl, it is preferred that said substituent is 4- CF_3 .

20 In still other preferred embodiments of the present invention, it is preferred that one of R_6 , R_7 and R_8 is a halogen, more preferably chloro and most preferably 4-chloro.

25

In yet other embodiments of the present invention, it is preferred that R_4 is $COOR_{15}$, and more preferably $COOH$.

30 In some preferred embodiments of the present invention, R_{10} is alkylidene and more preferably methylidene. In still other embodiments of the present invention R_9 is C_{1-6} alkyl and most preferably methyl. The double bond is present in preferred embodiments of the invention.

Preferred compounds of the present invention are:

35 (E)-2-[2-Methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid lithium salt;

2-[3-(4-Trifluoromethyl-phenyl)propionyl-amino]-benzoic acid;
(E)-2-[3-(4-Bromo-phenyl)-acryloylamino]-benzoic acid;
(E)-2-[3[(4-Trifluoromethyl-phenyl)acryloyl-amino]-benzoic acid;
(E)-2-[3[(4-Trifluoromethyl-phenyl)-acryloylamino]-benzoic acid lithium salt
5 hemihydrate;
2-[3-(4-Trifluoromethyl-phenyl)-but-3-enoylamino]-benzoic acid;
(E)-2-[3-(4-Trifluoromethyl-phenyl)-but-2-enoylamino]-benzoic acid sodium salt;
(E)-5-Chloro-2-[2-methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
(E)-5-Chloro-2-[2-methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid
10 lithium salt hemihydrate;
(E)-4-Chloro-2-[2-methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
(E)-4-Chloro-2-[2-methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid
lithium salt hemihydrate;
(E)-2-[2-Methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-nicotinic acid;
15 (E)-5-Methoxy-2-[2-methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
(E)-2-[2-Methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid diethyl-
carbamoylmethyl ester;
2-(3-o-Tolyl-acryloylamino)-benzoic acid;
20 2-(2-Methyl-3-o-tolyl-acryloylamino)-benzoic acid;
3-(3-o-Tolyl-acryloylamino)-benzoic acid;
3-(2-Methyl-3-o-tolyl-acryloylamino)-benzoic acid;
4-Chloro-2-(3-o-tolyl-acryloylamino)-benzoic acid;
4-Chloro-2-(2-methyl-3-o-tolyl-acryloylamino)-benzoic acid;
25 4-Chloro-3-(3-o-tolyl-acryloylamino)-benzoic acid;
4-Chloro-3-(2-methyl-3-o-tolyl-acryloylamino)-benzoic acid;
5-Chloro-2-(3-o-tolyl-acryloylamino)-benzoic acid;
5-Chloro-2-(2-methyl-3-o-tolyl-acryloylamino)-benzoic acid;
2-(3-m-Tolyl-acryloylamino)-benzoic acid;
30 2-(2-Methyl-3-m-tolyl-acryloylamino)-benzoic acid;
3-(3-m-Tolyl-acryloylamino)-benzoic acid;
3-(2-Methyl-3-m-tolyl-acryloylamino)-benzoic acid;
4-Chloro-2-(3-m-tolyl-acryloylamino)-benzoic acid;
4-Chloro-2-(2-methyl-3-m-tolyl-acryloylamino)-benzoic acid;
35 4-Chloro-3-(3-m-tolyl-acryloylamino)-benzoic acid;

- 7 -

4-Chloro-3-(2-methyl-3-m-tolyl-acryloylamino)-benzoic acid;
5-Chloro-2-(3-m-tolyl-acryloylamino)-benzoic acid;
5-Chloro-2-(2-methyl-3-m-tolyl-acryloylamino)-benzoic acid;
2-(3-p-Tolyl-acryloylamino)-benzoic acid;
5 2-(2-Methyl-3-p-tolyl-acryloylamino)-benzoic acid;
3-(3-p-Tolyl-acryloylamino)-benzoic acid;
3-(2-Methyl-3-p-tolyl-acryloylamino)-benzoic acid;
4-Chloro-2-(3-p-tolyl-acryloylamino)-benzoic acid;
4-Chloro-2-(2-methyl-3-p-tolyl-acryloylamino)-benzoic acid;
10 4-Chloro-3-(3-p-tolyl-acryloylamino)-benzoic acid;
4-Chloro-3-(2-methyl-3-p-tolyl-acryloylamino)-benzoic acid;
5-Chloro-2-(3-p-tolyl-acryloylamino)-benzoic acid;
5-Chloro-2-(2-methyl-3-p-tolyl-acryloylamino)-benzoic acid;
2-[3-(2-Fluoro-phenyl)-acryloylamino]-benzoic acid;
15 2-[3-(2-Fluoro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
3-[3-(2-Fluoro-phenyl)-acryloylamino]-benzoic acid;
3-[3-(2-Fluoro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
4-Chloro-2-[3-(2-fluoro-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-2-[3-(2-fluoro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
20 4-Chloro-3-[3-(2-fluoro-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-3-[3-(2-fluoro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
5-Chloro-2-[3-(2-fluoro-phenyl)-acryloylamino]-benzoic acid;
5-Chloro-2-[3-(2-fluoro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
2-[3-(3-Fluoro-phenyl)-acryloylamino]-benzoic acid;
25 2-[3-(3-Fluoro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
3-[3-(3-Fluoro-phenyl)-acryloylamino]-benzoic acid;
3-[3-(3-Fluoro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
4-Chloro-2-[3-(3-fluoro-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-2-[3-(3-fluoro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
30 4-Chloro-3-[3-(3-fluoro-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-3-[3-(3-fluoro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
5-Chloro-2-[3-(3-fluoro-phenyl)-acryloylamino]-benzoic acid;
5-Chloro-2-[3-(3-fluoro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
2-[3-(4-Fluoro-phenyl)-acryloylamino]-benzoic acid;
35 2-[3-(4-Fluoro-phenyl)-2-methyl-acryloylamino]-benzoic acid;

3-[3-(4-Fluoro-phenyl)-acryloylamino]-benzoic acid;
3-[3-(4-Fluoro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
4-Chloro-2-[3-(4-fluoro-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-2-[3-(4-fluoro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
5 4-Chloro-3-[3-(4-fluoro-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-3-[3-(4-fluoro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
5-Chloro-2-[3-(4-fluoro-phenyl)-acryloylamino]-benzoic acid;
5-Chloro-2-[3-(4-fluoro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
2-[3-(2-Chloro-phenyl)-acryloylamino]-benzoic acid;
10 2-[3-(2-Chloro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
3-[3-(2-Chloro-phenyl)-acryloylamino]-benzoic acid;
3-[3-(2-Chloro-phenyl)-2-methyl-acryloylamino]-benzoic acid;;
4-Chloro-2-[3-(2-chloro-phenyl)-acryloylamino]-benzoic acid;;
4-Chloro-2-[3-(2-chloro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
15 4-Chloro-3-[3-(2-chloro-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-3-[3-(2-chloro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
5-Chloro-2-[3-(2-chloro-phenyl)-acryloylamino]-benzoic acid;
5-Chloro-2-[3-(2-chloro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
2-[3-(3-Chloro-phenyl)-acryloylamino]-benzoic acid;
20 2-[3-(3-Chloro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
3-[3-(3-Chloro-phenyl)-acryloylamino]-benzoic acid;
3-[3-(3-Chloro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
4-Chloro-2-[3-(3-chloro-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-2-[3-(3-chloro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
25 4-Chloro-3-[3-(3-chloro-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-3-[3-(3-chloro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
5-Chloro-2-[3-(3-chloro-phenyl)-acryloylamino]-benzoic acid;
5-Chloro-2-[3-(3-chloro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
2-[3-(2-Bromo-phenyl)-acryloylamino]-benzoic acid;
30 2-[3-(2-Bromo-phenyl)-2-methyl-acryloylamino]-benzoic acid;
2-[3-(2-Bromo-phenyl)-2-methyl-acryloylamino]-benzoic acid;
3-[3-(2-Bromo-phenyl)-acryloylamino]-benzoic acid;
3-[3-(2-Bromo-phenyl)-2-methyl-acryloylamino]-benzoic acid;
2-[3-(2-Bromo-phenyl)-acryloylamino]-4-chloro-benzoic acid;
35 2-[3-(2-Bromo-phenyl)-2-methyl-acryloylamino]-4-chloro-benzoic acid;

3-[3-(2-Bromo-phenyl)-acryloylamino]-4-chloro-benzoic acid;
3-[3-(2-Bromo-phenyl)-2-methyl-acryloylamino]-4-chloro-benzoic acid;
2-[3-(2-Bromo-phenyl)-acryloylamino]-5-chloro-benzoic acid;
2-[3-(2-Bromo-phenyl)-2-methyl-acryloylamino]-5-chloro-benzoic acid;
5 2-[3-(3-Bromo-phenyl)-acryloylamino]-benzoic acid;
2-[3-(3-Bromo-phenyl)-2-methyl-acryloylamino]-benzoic acid; 3-[3-(3-Bromo-phenyl)-acryloylamino]-benzoic acid;
3-[3-(3-Bromo-phenyl)-2-methyl-acryloylamino]-benzoic acid;
2-[3-(3-Bromo-phenyl)-acryloylamino]-4-chloro-benzoic acid;
10 2-[3-(3-Bromo-phenyl)-2-methyl-acryloylamino]-4-chloro-benzoic acid;
3-[3-(3-Bromo-phenyl)-acryloylamino]-4-chloro-benzoic acid;
3-[3-(3-Bromo-phenyl)-2-methyl-acryloylamino]-4-chloro-benzoic acid;
2-[3-(3-Bromo-phenyl)-acryloylamino]-5-chloro-benzoic acid;
2-[3-(3-Bromo-phenyl)-2-methyl-acryloylamino]-5-chloro-benzoic acid;
15 2-[3-(2-Trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
2-[2-Methyl-3-(2-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
3-[3-(2-Trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
3-[2-Methyl-3-(2-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-2-[3-(2-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
20 4-Chloro-2-[2-methyl-3-(2-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-3-[3-(2-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-3-[2-methyl-3-(2-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
5-Chloro-2-[3-(2-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
5-Chloro-2-[2-methyl-3-(2-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
25 2-[3-(3-Trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
2-[2-Methyl-3-(3-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
3-[3-(3-Trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
3-[2-Methyl-3-(3-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-2-[3-(3-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
30 4-Chloro-2-[2-methyl-3-(3-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-3-[3-(3-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-3-[2-methyl-3-(3-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
5-Chloro-2-[3-(3-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
5-Chloro-2-[2-methyl-3-(3-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
35 2-[3-(4-Trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;

- 10 -

2-[2-Methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
3-[3-(4-Trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
3-[2-Methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-2-[3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
5 4-Chloro-2-[2-methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-3-[3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-3-[2-methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
5-Chloro-2-[3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
5-Chloro-2-[2-methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid;
10 2-(3-Phenyl-acryloylamino)-benzoic acid;
2-(2-Methyl-3-phenyl-acryloylamino)-benzoic acid;
3-(3-Phenyl-acryloylamino)-benzoic acid;
3-(2-Methyl-3-phenyl-acryloylamino)-benzoic acid;
4-Chloro-2-(3-phenyl-acryloylamino)-benzoic acid;
15 4-Chloro-2-(2-methyl-3-phenyl-acryloylamino)-benzoic acid;
4-Chloro-3-(3-phenyl-acryloylamino)-benzoic acid;
4-Chloro-3-(2-methyl-3-phenyl-acryloylamino)-benzoic acid;
5-Chloro-2-(3-phenyl-acryloylamino)-benzoic acid;
5-Chloro-2-(2-methyl-3-phenyl-acryloylamino)-benzoic acid;
20 2-[3-(4-Chloro-phenyl)-acryloylamino]-benzoic acid;
2-[3-(4-Chloro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
3-[3-(4-Chloro-phenyl)-acryloylamino]-benzoic acid;
3-[3-(4-Chloro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
4-Chloro-2-[3-(4-chloro-phenyl)-acryloylamino]-benzoic acid;
25 4-Chloro-2-[3-(4-chloro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
4-Chloro-3-[3-(4-chloro-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-3-[3-(4-chloro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
5-Chloro-2-[3-(4-chloro-phenyl)-acryloylamino]-benzoic acid;
5-Chloro-2-[3-(4-chloro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
30 2-[3-(4-Bromo-phenyl)-acryloylamino]-benzoic acid;
2-[3-(4-Bromo-phenyl)-2-methyl-acryloylamino]-benzoic acid;
3-[3-(4-Bromo-phenyl)-acryloylamino]-benzoic acid;
3-[3-(4-Bromo-phenyl)-2-methyl-acryloylamino]-benzoic acid;
2-[3-(4-Bromo-phenyl)-acryloylamino]-4-chloro-benzoic acid;
35 2-[3-(4-Bromo-phenyl)-2-methyl-acryloylamino]-4-chloro-benzoic acid;

- 11 -

- 3-[3-(4-Bromo-phenyl)-acryloylamino]-4-chloro-benzoic acid;
- 3-[3-(4-Bromo-phenyl)-2-methyl-acryloylamino]-4-chloro-benzoic acid;
- 2-[3-(4-Bromo-phenyl)-acryloylamino]-5-chloro-benzoic acid;
- 2-[3-(4-Bromo-phenyl)-2-methyl-acryloylamino]-5-chloro-benzoic acid;
- 5 2-[3-(2-Methoxy-phenyl)-acryloylamino]-benzoic acid;
- 2-[3-(2-Methoxy-phenyl)-2-methyl-acryloylamino]-benzoic acid;
- 3-[3-(2-Methoxy-phenyl)-acryloylamino]-benzoic acid;
- 3-[3-(2-Methoxy-phenyl)-2-methyl-acryloylamino]-benzoic acid;
- 4-Chloro-2-[3-(2-methoxy-phenyl)-acryloylamino]-benzoic acid;
- 10 4-Chloro-2-[3-(2-methoxy-phenyl)-2-methyl-acryloylamino]-benzoic acid;
- 4-Chloro-3-[3-(2-methoxy-phenyl)-acryloylamino]-benzoic acid;
- 4-Chloro-3-[3-(2-methoxy-phenyl)-2-methyl-acryloylamino]-benzoic acid;
- 5-Chloro-2-[3-(2-methoxy-phenyl)-acryloylamino]-benzoic acid;
- 5-Chloro-2-[3-(2-methoxy-phenyl)-2-methyl-acryloylamino]-benzoic acid;
- 15 2-[3-(3-Methoxy-phenyl)-acryloylamino]-benzoic acid;
- 2-[3-(3-Methoxy-phenyl)-2-methyl-acryloylamino]-benzoic acid;
- 3-[3-(3-Methoxy-phenyl)-acryloylamino]-benzoic acid;
- 3-[3-(3-Methoxy-phenyl)-2-methyl-acryloylamino]-benzoic acid;
- 4-Chloro-2-[3-(3-methoxy-phenyl)-acryloylamino]-benzoic acid;
- 20 4-Chloro-2-[3-(3-methoxy-phenyl)-2-methyl-acryloylamino]-benzoic acid;
- 4-Chloro-3-[3-(3-methoxy-phenyl)-acryloylamino]-benzoic acid;
- 4-Chloro-3-[3-(3-methoxy-phenyl)-2-methyl-acryloylamino]-benzoic acid;
- 5-Chloro-2-[3-(3-methoxy-phenyl)-acryloylamino]-benzoic acid;
- 5-Chloro-2-[3-(3-methoxy-phenyl)-2-methyl-acryloylamino]-benzoic acid;
- 25 2-[3-(4-Methoxy-phenyl)-acryloylamino]-benzoic acid;
- 2-[3-(4-Methoxy-phenyl)-2-methyl-acryloylamino]-benzoic acid;
- 3-[3-(4-Methoxy-phenyl)-acryloylamino]-benzoic acid;
- 3-[3-(4-Methoxy-phenyl)-2-methyl-acryloylamino]-benzoic acid;
- 4-Chloro-2-[3-(4-methoxy-phenyl)-acryloylamino]-benzoic acid;
- 30 4-Chloro-2-[3-(4-methoxy-phenyl)-2-methyl-acryloylamino]-benzoic acid;
- 4-Chloro-3-[3-(4-methoxy-phenyl)-acryloylamino]-benzoic acid;
- 4-Chloro-3-[3-(4-methoxy-phenyl)-2-methyl-acryloylamino]-benzoic acid;
- 5-Chloro-2-[3-(4-methoxy-phenyl)-acryloylamino]-benzoic acid;
- 5-Chloro-2-[3-(4-methoxy-phenyl)-2-methyl-acryloylamino]-benzoic acid;
- 35 2-[3-(2-Nitro-phenyl)-acryloylamino]-benzoic acid;

2-[2-Methyl-3-(2-nitro-phenyl)-acryloylamino]-benzoic acid;
3-[3-(2-Nitro-phenyl)-acryloylamino]-benzoic acid;
3-[2-Methyl-3-(2-nitro-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-2-[3-(2-nitro-phenyl)-acryloylamino]-benzoic acid;

5 4-Chloro-2-[2-methyl-3-(2-nitro-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-3-[3-(2-nitro-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-3-[2-methyl-3-(2-nitro-phenyl)-acryloylamino]-benzoic acid;
5-Chloro-2-[3-(2-nitro-phenyl)-acryloylamino]-benzoic acid;
5-Chloro-2-[2-methyl-3-(2-nitro-phenyl)-acryloylamino]-benzoic acid;

10 2-[3-(3-Nitro-phenyl)-acryloylamino]-benzoic acid;
2-[2-Methyl-3-(3-nitro-phenyl)-acryloylamino]-benzoic acid;
3-[3-(3-Nitro-phenyl)-acryloylamino]-benzoic acid;
3-[2-Methyl-3-(3-nitro-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-2-[3-(3-nitro-phenyl)-acryloylamino]-benzoic acid;

15 4-Chloro-2-[2-methyl-3-(3-nitro-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-3-[3-(3-nitro-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-3-[2-methyl-3-(3-nitro-phenyl)-acryloylamino]-benzoic acid;
5-Chloro-2-[3-(3-nitro-phenyl)-acryloylamino]-benzoic acid;
5-Chloro-2-[2-methyl-3-(3-nitro-phenyl)-acryloylamino]-benzoic acid;

20 2-[3-(4-Nitro-phenyl)-acryloylamino]-benzoic acid;
2-[2-Methyl-3-(4-nitro-phenyl)-acryloylamino]-benzoic acid;
3-[3-(4-Nitro-phenyl)-acryloylamino]-benzoic acid;
3-[2-Methyl-3-(4-nitro-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-2-[3-(4-nitro-phenyl)-acryloylamino]-benzoic acid;

25 4-Chloro-2-[2-methyl-3-(4-nitro-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-3-[3-(4-nitro-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-3-[2-methyl-3-(4-nitro-phenyl)-acryloylamino]-benzoic acid;
5-Chloro-2-[3-(4-nitro-phenyl)-acryloylamino]-benzoic acid;
5-Chloro-2-[2-methyl-3-(4-nitro-phenyl)-acryloylamino]-benzoic acid;

30 2-[3-(4-Dimethylamino-phenyl)-acryloylamino]-benzoic acid;
2-[3-(4-Dimethylamino-phenyl)-2-methyl-acryloylamino]-benzoic acid;
3-[3-(4-Dimethylamino-phenyl)-acryloylamino]-benzoic acid;
3-[3-(4-Dimethylamino-phenyl)-2-methyl-acryloylamino]-benzoic acid;
4-Chloro-2-[3-(4-dimethylamino-phenyl)-acryloylamino]-benzoic acid;

35 4-Chloro-2-[3-(4-dimethylamino-phenyl)-2-methyl-acryloylamino]-benzoic acid;

- 13 -

4-Chloro-3-[3-(4-dimethylamino-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-3-[3-(4-dimethylamino-phenyl)-2-methyl-acryloylamino]-benzoic acid;
5-Chloro-2-[3-(4-dimethylamino-phenyl)-acryloylamino]-benzoic acid;
5-Chloro-2-[3-(4-dimethylamino-phenyl)-2-methyl-acryloylamino]-benzoic acid;
5 2-[3-(2,4-Dichloro-phenyl)-acryloylamino]-benzoic acid;
2-[3-(2,4-Dichloro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
3-[3-(2,4-Dichloro-phenyl)-acryloylamino]-benzoic acid;
3-[3-(2,4-Dichloro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
→ 4-Chloro-2-[3-(2,4-dichloro-phenyl)-acryloylamino]-benzoic acid;
10 4-Chloro-2-[3-(2,4-dichloro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
4-Chloro-3-[3-(2,4-dichloro-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-3-[3-(2,4-dichloro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
5-Chloro-2-[3-(2,4-dichloro-phenyl)-acryloylamino]-benzoic acid;
5-Chloro-2-[3-(2,4-dichloro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
15 2-[3-(3,4-Dichloro-phenyl)-acryloylamino]-benzoic acid;
2-[3-(3,4-Dichloro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
3-[3-(3,4-Dichloro-phenyl)-acryloylamino]-benzoic acid;
3-[3-(3,4-Dichloro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
4-Chloro-2-[3-(3,4-dichloro-phenyl)-acryloylamino]-benzoic acid;
20 4-Chloro-2-[3-(3,4-dichloro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
4-Chloro-3-[3-(3,4-dichloro-phenyl)-acryloylamino]-benzoic acid;
4-Chloro-3-[3-(3,4-dichloro-phenyl)-2-methyl-acryloylamino]-benzoic acid;
→ 5-Chloro-2-[3-(3,4-dichloro-phenyl)-acryloylamino]-benzoic acid; and
5-Chloro-2-[3-(3,4-dichloro-phenyl)-2-methyl-acryloylamino]-benzoic acid; or
25 pharmaceutical salts thereof.

It is understood that the definition of compounds of formula (I), when R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , and R_{10} contain asymmetric carbons, encompass all possible stereoisomers and mixtures thereof which possess the activity discussed below. In particular, the definition encompasses racemic modifications and any optical isomers which possess the indicated activity. Optical isomers may be obtained in pure form by standard separation techniques or enantiomer specific synthesis. It is understood that this invention encompasses all crystalline forms of compounds of formula (I). The pharmaceutically acceptable salts of the basic compounds of this

- 14 -

invention are those derived from such organic and inorganic acids as: lactic, citric, acetic, tartaric, fumaric, succinic, maleic, malonic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, and similarly known acceptable acids. Where R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_8 , R_9 , and R_{10} contains a carboxyl group, salts of the 5 compounds in this invention may be formed with bases such as alkali metals (Na, K, Li) or alkaline earth metals (Ca or Mg).

"Alkyl" as used herein means a branched or straight chain having from 1 to 12 carbon atoms and more preferably from 1 to 6 carbon atoms. Exemplary alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl and hexyl.

10 "Alkenyl" as used herein means a branched or straight chain having from 2 to 12 carbon atoms and more preferably from 1 to 6 carbon atoms, the chain containing at least one carbon-carbon double bond. Alkenyl, may be used synonymously with the term olefin and includes alkylidenes. Exemplary alkenyl groups include ethylene, propylene and isobutylene.

15 "Alkoxy" as used herein means an alkyl-O group in which the alkyl group is as previously described. Exemplary alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, and t-butoxy.

20 "Haloalkyl" as used herein refers to an alkyl group, as defined above, in which one or more hydrogen atoms are replaced with a halogen. Perhaloalkyl refers to alkyl groups in which each of the hydrogens are replaced with halogen atoms. Exemplary haloalkyl groups include chloromethyl, dibromomethyl, and the perhaloalkyl, trifluoromethyl.

25 "Aryl" as used herein means mono or bicyclic aromatic ring having from 6 to 12 carbon atoms. Monocyclic rings preferably have 6 or 7 members and bicyclic rings preferably have 8, 9 or 10 membered ring structures. Exemplary aryl groups include phenyl and naphthyl. The aryl group may be substituted with one or more substituents. Substituted aryl groups preferably have one to three substituents which may include alkyl, alkoxy, perhaloalkyl, halogen, nitro, amino, carboxy, carboxyalkyl, alkylamino, and dialkylamino.

30 "Aralkyl" as used herein means an aryl-alkyl group in which the aryl and alkyl group are previously defined. Exemplary aralkyl groups include benzyl and phenethyl.

"Alkanoyl" as used herein refers to $-C(O)R$ where R is alkyl as previously defined.

"Aryloyl" as used herein refers to $-C(O)R$ where R is aryl as previously defined.

- 15 -

"Aralkanoyl" as used herein refers to $-C(O)R$ where R is aralkyl as previously defined.

"Carboxamido" as used herein refers to $-CONH_2$.

5 "Sulfamoyl" as used herein refers to $-SONH_2$.

"Sulfamido" as used herein refers to $-RSONH_2$. Thus, alkyl-, aryl, and aralkylsulfamido refer to groups in which the R is alkyl, aryl or aralkyl as previously defined.

10 "Sulfinyl" as used herein refers to the radical $-SOR$. Thus, alkyl-, aryl-, and aralkylsulfinyl refer to groups in which the R is alkyl, aryl or aralkyl, as previously defined.

15 "Sulfonyl" as used herein refers to the radical $-SO_2R$. Thus, alkyl-, aryl-, and aralkylsulfonyl refer to groups in which the R is alkyl, aryl or aralkyl, as previously defined.

"Halogen", as used herein means chloro, fluoro, bromo and iodo.


20 Carbon number refers to the number of carbons in the carbon backbone and does not include carbon atoms occurring in substituents such as an alkyl or alkoxy substituents.

25 Where terms are used in combination, the definition for each individual part of the combination applies unless defined otherwise. For instance, perhaloalkoxy refers to an alkoxy group, as defined above, in which each hydrogen atoms of the alkyl group has been replaced by a halogen.

30 The present invention also provides a process for the preparation of compounds of formula (I). Methods of preparation are shown in **Schemes 1** and **2**. Starting materials (II) and (III) are allowed to react (**Scheme 1**) in the presence of an appropriate base such as, but not limited to, *n*-butyllithium, *sec*-butyllithium, *tert*-butyllithium, lithium diisopropylamide, lithium, potassium or sodium hexamethyldisilazide, or lithium, potassium or sodium tetramethylpiperadide,

- 16 -

Scheme 1




to give condensation product (IV), wherein R₁, R₂, R₃, R₉, and R₁₀, respectively, are as defined hereinbefore, or a group of atoms convertible thereto. Saponification of 5 the ester provides the intermediate carboxylic acid (V).

Carboxylic acid intermediate (V) can subsequently be coupled (Scheme 2) to the amine of an appropriately derivatized anthranilic acid of the formula (VI) or (VII) utilizing one of the following established coupling procedures (Method A: (COCl)₂, cat. 10 DMF, CH₂Cl₂, then add the neat acid chloride to a solution of anthranilic acid in sodium hydroxide; Method B: diisopropylcarbodiimide, DMAP, CH₂Cl₂, then add methyl anthranilate; or Method C: (COCl)₂, cat. DMF, CH₂Cl₂, or SOCl₂ followed by treatment of the neat acid chloride with triethylamine and methyl anthranilate) to afford amides of formula (Ia) or (Ib). If the esters of (VI) or (VII) are used, then final 15 saponification affords the free acids (R₁₅=H).

- 17 -

Scheme 2



In addition to CH_2Cl_2 , the reactions mentioned above may be carried out in aprotic solvents such as diethyl ether, dichloroethane, dioxane or THF at low to ambient 5 temperatures. Where sodium hydroxide is used as a base, other inorganic bases which may also suffice are lithium hydroxide or potassium hydroxide, etc. Likewise, triethylamine may be optionally substituted with any trialkylamine.

Compounds of Formula (I) may also be prepared using solid phase synthesis.

10

As mentioned previously, the compounds of formula (I), and their pharmaceutically acceptable salts have been found to relax smooth muscle. They are therefore useful in the treatment of disorders associated with smooth muscle contraction, disorders involving excessive smooth muscle contraction of the urinary 15 tract (such as incontinence), or of the gastro-intestinal tract (such as irritable bowel syndrome), asthma, and hair loss. Furthermore, the compounds of formula (I) are active as potassium channel activators which render them useful for treatment of peripheral vascular disease, congestive heart failure, stroke, anxiety, cerebral anoxia and other neurodegenerative disorders. Moreover, compounds of formula (I) may also

be active as chloride channel blockers, which again renders them useful for treatment of the above stated disorders.

Compounds of the present invention are characterized by their potent smooth muscle relaxing properties *in vitro*. The compounds of this invention exert their smooth muscle relaxatory activity via activation of potassium channels and/or blocking of chloride channels. Members of this series are expected to be active *in vivo* as evidenced by *in vivo* activity shown in a model of rat bladder hypertrophy (Table II). In addition, the compounds of the present invention are unique in that they possess intrinsic selectivity for bladder tissue over vascular tissue as demonstrated by bladder/aorta IC₅₀ ratios (Table 1). Comparative compound, Tranilast[®] was shown not to be a potent or bladder selective smooth muscle relaxant.

The present invention accordingly provides a pharmaceutical composition which comprises a compound of this invention in combination or association with a pharmaceutically acceptable carrier. In particular, the present invention provides a pharmaceutical composition which comprises an effective amount of a compound of this invention and a pharmaceutically acceptable carrier.

The compositions are preferably adapted for oral administration. However, they may also be adapted for other modes of administration, for example, parenteral administration for patients suffering from heart failure or intransally for patients suffering from asthma.

In order to obtain consistency of administration, it is preferred that a composition of the invention is in the form of a unit dose. Suitable unit dose forms include tablets, capsules and powders in sachets or vials. Such unit dose forms may contain from 0.1 to 100 mg of a compound of the invention and preferably from 2 to 50 mg. Still further preferred unit dosage forms contain 5 to 25 mg of a compound of the present invention. The compounds of the present invention can be administered orally at a dose range of about 0.01 to 100 mg/kg or preferably at a dose range of 0.1 to 10 mg/kg. Such compositions may be administered from 1 to 6 times a day, more usually from 1 to 4 times a day.

- 19 -

The compositions of the invention may be formulated with conventional excipients, such as a filler, a disintegrating agent, a binder, a lubricant, a flavoring agent and the like. They are formulated in conventional manner, for example, in a manner similar to that used for known antihypertensive agents, diuretics and β -blocking agents.

The present invention further provides a compound of the invention for use as an active therapeutic substance. Compounds of formula (I) are of particular use in the induction of smooth muscle relaxation.

10

The present invention further provides a method of treating smooth muscle disorders in mammals including man, which comprises administering to the afflicted mammal an effective amount of a compound or a pharmaceutical composition of the invention.

15

The following examples are presented to illustrate rather than limit the methods for production of representative compounds of the invention.

EXAMPLES

20

Example 1

(E)-2-[2-Methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid lithium salt

25

Step 1) Preparation of (E)-[2-methyl-3-(4-trifluoromethylphenyl)]-2-propenoic acid methyl ester

To a solution of 2.5 M *n*-butyllithium (25.3 mL, 63.2 mmol) in hexanes and 30 THF (50 mL) at -25°C was added via syringe pump over 22 min methyl 2-diethylphosphonopropionate (13.7 mL, 68.9 mmol). The resultant mixture was stirred an additional 0.5 h at -25°C, whereupon it was chilled to -80°C. To this was added via syringe pump over 30 min α,α,α -trifluoro-*p*-tolualdehyde (10.0 g, 57.4 mmol) as a solution in THF (15 mL). Upon completed addition, the cooling bath was allowed to 35 warm very slowly to 10°C over a period of 12 h. The reaction mixture was

- 20 -

subsequently quenched with MeOH (1.0 mL), and all volatiles were removed by rotary evaporation. The residue was then partitioned between ether (250 mL) and water (100 mL). The organic phase was washed with brine (100 mL) and dried over MgSO₄. Submission of the crude product to flash chromatography (elution with 2% ether-hexanes) afforded upon concentration 11.32 g (81%) of a white solid: ¹H NMR (DMSO-*d*₆) δ 7.66-7.79 (m, 5 H), 3.77 (s, 3 H), 2.04 (d, 3 H).

10 **Step 2)** Preparation of (E)-[2-methyl-3-(4-trifluoromethylphenyl)]-2-propenoic acid

To a homogeneous solution of the above methyl ester (11.2 g, 45.9 mmol) in THF (320 mL) at RT was added 1.00 N LiOH (138 mL, 138 mmol). The resulting biphasic mixture was stirred vigorously for 16 h, whereupon all volatiles were removed by rotary evaporation. The leftover aqueous solution was washed with ether (3 x 100 mL), acidified to pH 2 with concentrated HCl (13.4 mL), and partitioned with ether (300 mL). The aqueous phase was then saturated with solid NH₄Cl, and extracted again (2 x 150 mL). The combined organic extracts were dried over MgSO₄, treated with Norite, filtered through celite, and concentrated to a solid. Trituration with ether-hexanes followed by filtration and drying *in vacuo* yielded 8.60 g (81%) of a white solid: ¹H NMR (DMSO-*d*₆) δ 12.69 (s, 1 H), 7.62-7.79 (m, 5 H), 2.01 (d, 3 H).

15 **Step 3)** Preparation of (E)-2-[2-Methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid

20 To a heterogeneous mixture of the above carboxylic acid (1.00 g, 4.34 mmol) and anhydrous DMF (2 drops) in anhydrous CH₂Cl₂ (5 mL) at 0°C was added dropwise oxalyl chloride (760 μL, 8.69 mmol). The resultant mixture was warmed to RT and stirred for 2.5 h, whereupon it was concentrated to a heterogeneous yellow mixture and purged of excess oxalyl chloride *in vacuo*. The acid chloride was then 25 added to a homogeneous solution of anthranilic acid (1.19 g, 8.69 mmol) in 2.5 N aqueous NaOH (6.95 mL, 17.4 mmol) at 5°C, resulting in the instantaneous formation of a white precipitate. The reaction mixture was then warmed to RT, whereupon it was 30 diluted with a minimal amount of water to facilitate stirring, which was continued for an additional 1.5 h. The mixture was acidified to pH 2 by addition of concentrated HCl (1.63 mL), diluted with 2.0 N HCl, and stirred for 1.5 h. Filtration of the suspension 35

- 21 -

followed by washing with water, air drying and subsequent recrystallization from MeOH afforded 568 mg (37%) of a highly crystalline white solid: mp 207-208°C; ¹H NMR (DMSO-*d*₆) δ 13.76 (br s, 1 H), 8.68 (dd, 1 H), 8.04 (dd, 1 H), 7.56-7.81 (m, 6 H), 7.19 (ddd, 1 H), 2.18 (d, 1 H); IR (KBr) 3396, 3116, 2722, 2651, 1674, 1607, 5 1584, 1534, 1471, 1452, 1411, 1382, 1328, 1291, 1260, 1198, 1166, 1118, 1107, 1068, 1016, 996, 903, 824, 757, 696, 664 cm⁻¹; MS (m/z) 349 [M⁺].

Elemental analysis for C₁₈H₁₄F₃NO₃:

10 Calc'd: C, 61.89; H, 4.04; N, 4.01.
Found: C, 61.87; H, 4.04; N, 4.01.

Step 4) Preparation of (E)-2-[2-Methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid lithium salt

15 To a solid mixture of the above carboxylic acid (4.907 g, 14.05 mmol) and lithium hydride dust (111.7 mg, 14.05 mmol) under an atmosphere of N₂ was added THF (90 mL, distilled from sodium benzophenone ketyl), at RT. The heterogeneous mixture was heated at reflux for 12 h, producing a copious white precipitate, whereupon it was cooled to RT, diluted with THF (1000 mL), filtered through celite, 20 and concentrated to a white solid. The solid was then triturated with ether (500 mL, distilled from sodium benzophenone ketyl) for 12 h, producing a fine white suspension, filtered over an atmosphere of N₂, washed with ether (500 mL), and finally dried under high vacuum at 80°C affording 4.2655 g (85%) of a white powder: mp 321.5-322.3°C(dec); ¹H NMR (DMSO-*d*₆) δ 15.21 (s, 1 H), 8.59 (dd, 1 H), 8.00 (dd, 1 H), 7.71 (ABq, 4 H), 7.51 (s, 1 H), 7.28 (ddd, 1 H), 6.95 (ddd, 1 H), 3.35 (s, 3 H); IR (KBr) 3354, 3127, 1647, 1623, 1598, 1527, 1453, 1388, 1325, 1251, 1191, 25 1127, 1068, 1018, 998, 915, 862, 830, 763, 704 cm⁻¹; MS (m/z) 348 [(M-Li)⁺].

Elemental analysis for C₁₈H₁₃F₃LiNO₃:

30 Calc'd: C, 60.85; H, 3.70; N, 3.94.
Found: C, 60.34; H, 3.50; N, 3.80.

- 22 -

Example 2

2-[3-(4-Trifluoromethyl-phenyl)-propionylamino]-benzoic acid

5

A mixture of 3-(4-trifluoromethylphenyl)-propionic acid (2.14 g, 10.0 mmol) and thionyl chloride (0.80 mL, 11.0 mmol) was heated to reflux in benzene (100 mL) until all starting material was consumed as indicated by TLC. This mixture was concentrated via rotary evaporation providing the crude acid chloride, which was combined with anthranilic acid (1.37 g, 10.0 mmol) in dimethylacetamide (100 mL) and then refluxed for 12 h. The reaction mixture was cooled to RT, and partitioned between water and ether. The organic phase was dried over Na_2SO_4 , concentrated, triturated repeatedly with MeOH, then dried to yield 3.40 g (100%) of a white solid: mp 169-171°C; ^1H NMR ($\text{DMSO}-d_6$) δ 13.4-13.7 (br s, 1 H), 11.12 (s, 1 H), 8.45 (dd, 1 H), 7.63 (d, 2 H), 7.57 (ddd, 1 H), 7.50 (d, 2 H), 7.13 (ddd, 1 H), 3.03 (t, 2 H), 2.77 (t, 2 H); IR (KBr) 3124, 3036, 2983, 1711, 1661, 1609, 1585, 1335, 1315, 1224, 1192, 1163, 1145, 1122, 1107, 1070, 791, 760 cm^{-1} ; MS (m/z) 379 [M^+].

Elemental analysis for $C_{17}H_{14}F_3NO_3$:

20 Calc'd: C, 60.54; H, 4.18; N, 4.15.
Found: C, 60.27; H, 4.26; N, 4.19.

Example 3

25 (E)-2-[3-(4-Bromo-phenyl)-acryloylamino]-benzoic acid

Step 1) Preparation of (E)-2-[3-(4-Bromo-phenyl)-acryloylamino]-benzoic acid methyl ester

30 To a heterogeneous mixture of 4-bromocinnamic acid (2.25 g, 9.91 mmol) and DMAP (121 mg, 0.991 mmol) in CH_2Cl_2 at 0°C was added 1,3-diisopropyl-carbodiimide (1.55 mL, 9.91 mmol). The resultant mixture was stirred for 30 min, at which point was added methyl anthranilate (1.92 mL, 14.9 mmol). The reaction mixture was kept at 0°C for 10 min, and then allowed to warm to RT whereupon it was stirred for 72 h. The reaction mixture was then diluted with EtOAc (200 mL) and

- 23 -

successively partitioned with 2.0 N HCl (50 mL), water (50 mL), saturated NaHCO₃ (50 mL), and finally brine (50 mL). The organic phase was dried over MgSO₄, treated with Norite, filtered through celite, and concentrated to a solid. Trituration with ether-hexanes, followed by filtration, washing with 20% ether-petroleum ether and drying *in vacuo* afforded 2.81 g of crude white solid. Recrystallization from MeOH provided 1.59 g (45%) of analytically pure material as white crystalline plates: ¹H NMR (DMSO-*d*₆) δ 10.83 (s, 1 H), 8.39 (dd, 1 H), 7.94 (dd, 1 H), 7.71-7.56 (m, 6 H), 7.21 (ddd, 1 H), 6.97 (d, 1 H), 3.87 (s, 1 H).

10 **Step 2** (E)-2-[3-(4-Bromo-phenyl)-acryloylamino]-benzoic acid

In a manner similar to Example 1, Step 2 was prepared the title compound (781 mg, 52%): mp 215-216°C; ¹H NMR (DMSO-*d*₆) δ 13.52 (br s, 1 H), 11.33 (s, 1 H), 8.59 (dd, 1 H), 8.01 (dd, 1 H), 7.58-7.72 (m, 6H), 7.18 (ddd, 1 H), 6.94 (d, 1 H);
15 IR (KBr) 3331, 3123, 3072, 1705, 1670, 1626, 1606, 1583, 1526, 1487, 1449, 1413, 1402, 1389, 1261, 1224, 1146, 1071, 966, 882, 816, 750, 656 cm⁻¹; MS (m/z) 345/347 [M⁺].

Elemental analysis for C₁₆H₁₂BrNO₃:

20 Calc'd: C, 55.51; H, 3.49; N, 4.04.
Found: C, 55.10; H, 3.50; N, 4.10.

Example 4

25 (E)-2-[3-(4-Trifluoromethyl-phenyl)-acryloylamino]-benzoic acid

A mixture of trans-4-(trifluoromethyl)cinnamic acid (2.02 g, 9.34 mmol), thionyl chloride (2.0 mL, 27.4 mmol), and methyl anthranilate (2.4 mL, 13.6 mmol) were refluxed in benzene (100 mL) for 96 h. Concentration *in vacuo*, followed by 30 crystallization with MeOH afforded, upon filtration, 1.3 g (40%) of the intermediate methyl ester. To a solution of this intermediate (873 mg, 2.50 mmol) in THF (25 mL) was added 1N NaOH (7.5 mL, 7.5 mmol). The resulting mixture was stirred until hydrolysis was completed, whereupon it was acidified to pH 3 with HCl, and stirred for 30 min. The organic phase was separated, washed with brine, dried over MgSO₄, and then concentrated *in vacuo* yielding 500 mg (60%) of a white solid: mp 222-224°C;

- 24 -

¹H NMR (DMSO-d₆) δ 13.3-13.9 (br s, 1 H), 11.36 (s, 1 H), 8.59 (dd, 1 H), 8.01 (dd, 1 H), 7.97 (d, 2 H), 7.78 (d, 2 H), 7.69 (d, 1 H), 7.63 (ddd, 1 H), 7.20 (ddd, 1 H); IR (KBr) 3329, 3063, 2877, 1674, 1628, 1606, 1585, 1530, 1472, 1451, 1414, 1329, 1299, 1262, 1214, 1165, 1118, 1110, 1068, 972, 893, 831, 756, 657 cm⁻¹; MS 5 (m/z) 335 [M⁺].

Elemental analysis for C₁₇H₁₂F₃NO₃:

Calc'd: C, 60.90; H, 3.61; N, 4.18.

Found: C, 60.50; H, 3.55; N, 4.21.

10

Example 5

(E)-2-[3[(4-Trifluoromethyl-phenyl)-acryloylamino]-benzoic acid lithium salt hemihydrate

15

In a manner similar to Step 4 of Example 1 was prepared the title compound (64%) from the above carboxylic acid: mp >340°C (dec); ¹H NMR (DMSO-d₆) δ 15.03 (s, 1 H), 8.56 (dd, 1 H), 8.00 (dd, 1 H), 7.84 (ABq, 4 H), 7.61 (d, 1 H), 7.28 (ddd, 1 H), 6.96 (ddd, 1 H), 6.84 (d, 1 H); IR (KBr) 3715, 3678, 3423, 3264, 3060, 1693, 20 1620, 1587, 1512, 1415, 1384, 1294, 1166, 1111, 1067, 976, 828, 759 cm⁻¹; MS (m/z) 334 [(M-Li)⁺].

Elemental analysis for C₁₇H₁₁F₃NO₃Li • 0.5 H₂O:

Calc'd: C, 59.84; H, 3.26; N, 4.11.

25

Found: C, 58.78; H, 3.22; N, 4.06.

Example 6

2-[3-(4-Trifluoromethyl-phenyl)-but-3-enoylamino]-benzoic acid

30

Step 1) Preparation of (E)-[3-(4-trifluoromethyl-phenyl)]-but-2-enoic acid methyl ester.

In a manner similar to Step 1 of Example 1 was prepared the title intermediate (46%) from 4-(trifluoromethyl-phenyl)-acetophenone: ¹H NMR (DMSO-d₆) δ 7.77 (ABq, 4 H), 6.24 (q, 1 H), 3.68 (s, 3 H), 2.52 (d, 3 H).

- 25 -

Step 2) Preparation of (E)-[3-(4-trifluoromethyl-phenyl)]-but-2-enoic acid

In a manner similar to Step 2 of Example 1 was prepared the title intermediate 5 (82%) as a white solid: ^1H NMR (DMSO- d_6) δ 12.42 (s, 1 H), 7.75 (s, 4 H), 6.17 (q, 1 H).

Step 3) Preparation of 2-[3-(4-trifluoromethyl-phenyl)-but-3-enoylamino]-benzoic acid methyl ester

10

To a homogeneous solution of the above carboxylic acid (1.75 g, 7.60 mmol), DMAP (186 mg, 1.52 mmol) and methyl anthranilate (1.97 mL, 15.2 mmol) in CH_2Cl_2 was added dropwise at 0°C diisopropylcarbodiimide (1.19 mL, 7.60 mmol). The resultant yellow mixture was stirred at 0°C for 1 h, then warmed to RT and stirred for 15 an additional 48 h. The reaction mixture was diluted with ether (400 mL), extracted consecutively with water (3 x 200 mL) and brine (200 mL). The organic phase was dried over MgSO_4 , treated with 1.0 M ethereal HCl (8.0 mL, 8.0 mmol), filtered through a short pad of SiO_2 , then concentrated to an oily residue which was submitted to flash chromatography (elution with 20% ether-hexanes) affording 1.58 g (57%) as a 20 white solid: ^1H NMR (DMSO- d_6) δ 10.75 (s, 1 H), 8.26 (dd, 1 H), 7.88 (dd, 1 H), 7.73 (ABq, 4 H), 7.56 (ddd, 1 H), 7.15 (ddd, 1 H), 5.85 (s, 1 H), 5.55 (s, 1 H), 3.81 (s, 3 H), 3.75 (s, 2 H).

25

Step 4) Preparation of 2-[3-(4-Trifluoromethyl-phenyl)-but-3-enoylamino]-benzoic acid

The above ester was saponified as described in Step 2 of Example 1 to give a mixture of olefin isomers. To this mixture (325 mg, 0.930 mmol) was added ethereal 1.0 N HCl (30 mL, 30 mmol) at RT. The resultant homogeneous solution was stirred 30 for 20 min, then diluted to 200 mL with petroleum ether, resulting in the formation of a copious precipitate. This mixture was stirred 1 h, then filtered, and dried under high vacuum at 60°C to afford 218.7 mg (67%) of the terminal olefinic isomer as a white solid: mp 174-175°C; ^1H NMR (DMSO- d_6) δ 13.53 (br s, 1 H), 11.31 (s, 1 H), 8.45 (dd, 1 H), 7.93 (dd, 1 H), 7.72 (ABq, 4 H), 7.53 (ddd, 1 H), 7.11 (ddd, 1 H), 5.86 (s, 1 H), 5.57 (s, 1 H), 3.75 (s, 3 H); IR (KBr) 3183, 2993, 2651, 1694, 1635, 1582,

- 26 -

1511, 1451, 1406, 1325, 1235, 1176, 1064, 1014, 983, 940, 863, 797, 751, 727, 695 cm⁻¹; MS (m/z) 349 [M⁺].

Elemental analysis for C₁₈H₁₄F₃NO₃:

5 Calc'd: C, 61.89; H, 4.04; N, 4.01.
 Found: C, 61.81; H, 3.94; N, 4.22.

Example 7

10 (E)-2-[3-(4-Trifluoromethyl-phenyl)-but-2-enoylamino]-benzoic acid sodium salt

In a manner similar to Step 3 of Example 1 was prepared the title compound from (E)-[3-(4-trifluoromethyl-phenyl)]-but-2-enoic acid and anthranilic acid. The final 15 workup entailed treatment of the reaction mixture with sufficient 2.0 N HCl to bring the medium to neutrality. Following recrystallization from MeOH, 110 mg (8%) of the sodium salt was isolated as a hygroscopic white solid: mp 325-328°C; ¹H NMR (DMSO-d₆) δ 14.68 (s, 1 H), 8.54 (dd, 1 H), 7.98 (dd, 1 H), 7.77 (ABq, 4 H), 7.28 (ddd, 1 H), 6.95 (ddd, 1 H), 6.27 (d, 1 H), 2.57 (d, 3H); IR (KBr) 3439, 3236, 20 3157, 3024, 1665, 1618, 1589, 1441, 1383, 1326, 1304, 1168, 1120, 1080, 1066, 1014, 836, 760 cm⁻¹; MS (m/z) 349 [M⁺].

Elemental Analysis for C₁₈H₁₃F₃NO₃Na:

25 Calc'd: C, 58.23; H, 3.53; N, 3.77.
 Found: C, 57.38; H, 3.41; N, 3.72.

Example 8

30 (E)-5-Chloro-2-[2-methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid

In a manner similar to Step 3 of Example 1 was prepared the title compound (47%) from (E)-3-[4-trifluoromethylphenyl]-2-propenoic acid and 4-chloroanthranilic acid: mp 225.3-225.8°C; ¹H NMR (DMSO-d₆) δ 11.79 (s, 1 H), 8.68 (d, 1 H), 7.96 (d, 1 H), 7.73 (ABq, 4 H), 7.71 (dd, 1 H), 7.56 (s, 1 H), 2.17 (d, 3 H); IR (KBr) 35

- 27 -

3132, 1698, 1662, 1611, 1583, 1519, 1381, 1330, 1293, 1167, 1114, 1070, 1000, 847, 833, 688 cm⁻¹; MS (m/z) 383/385 [M⁺].

Elemental analysis for C₁₈H₁₃ClF₃NO₃:

5 Calc'd: C, 56.34; H, 3.41; N, 3.65.
 Found: C, 56.21; H, 3.20; N, 3.71.

Example 9

10 (E)-5-Chloro-2-[2-methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-
 benzoic acid lithium salt hemihydrate

In a manner similar to Step 4 of Example 1 was prepared the title compound (89%) from (E)-5-Chloro-2-[2-methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid as a hygroscopic white solid: mp 244.9-262°C; ¹H NMR (DMSO-d₆) δ 15.10 (s, 1 H), 8.62 (d, 1 H), 7.80 (ABq, 4 H), 7.50 (s, 1 H), 7.33 (dd, 1 H), 2.15 (d, 3 H); IR (KBr) 3750, 3413, 3124, 1657, 1616, 1583, 1512, 1441, 1412, 1374, 1325, 1251, 1204, 1167, 1126, 1068, 999, 830, 736, 697 cm⁻¹; MS (m/z) 396 [(M+H+Li)⁺].

20 Elemental analysis for C₁₈H₁₂ClF₃NO₃Li • 0.5 H₂O:
 Calc'd: C, 55.43; H, 3.08; N, 3.59.
 Found: C, 54.15; H, 3.12; N, 3.51.

25 Example 10

(E)-4-Chloro-2-[2-methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-
 benzoic acid

30 In a manner similar to Step 3 of Example 1 was prepared the title compound (36%) from (E)-3-[4-trifluoromethylphenyl]-2-propenoic acid and 5-chloroanthranilic acid: mp 228.4-229.0°C; ¹H NMR (DMSO-d₆) δ 11.97 (s, 1 H), 8.78 (d, 1 H), 8.03 (d, 1 H), 7.74 (ABq, 4 H), 7.57 (s, 1 H), 7.26 (dd, 1 H), 2.18 (d, 3 H); IR (KBr) 3420, 3225, 3010, 2930, 2600, 1710, 1660, 1615, 1600, 1420, 1345, 1295, 1115, 35 1075, 1000, 915, 850, 785, 725, 690 cm⁻¹; MS (m/z) 383/385 [M⁺].

- 28 -

Elemental analysis for $C_{18}H_{13}ClF_3NO_3$:

Calc'd: C, 56.34; H, 3.42; N, 3.65.
Found: C, 55.94; H, 3.23; N, 3.86.

5

Example 11

(E)-4-Chloro-2-[2-methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid lithium salt hemihydrate

10

In a manner similar to Step 4 of Example 1 was prepared the title compound (79%) from (E)-4-Chloro-2-[2-methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid as a hygroscopic white solid: mp 320.9-321.4°C (dec); 1H NMR (DMSO- d_6) δ 8.68 (d, 1 H), 8.00 (d, 1 H), 7.72 (ABq, 4 H), 7.52 (s, 1 H), 7.01 (dd, 1 H), 15 2.16 (d, 3 H); IR (KBr) 3662, 3405, 3103, 2994, 2647, 1659, 1618, 1573, 1512, 1440, 1373, 1327, 1242, 1167, 1110, 1068, 1000, 914, 847, 769, 693 cm^{-1} ; MS (m/z) 396 [(M+Li) $^+$], 390, [(M+H) $^+$].

Elemental analysis for $C_{18}H_{12}ClF_3NO_3Li \cdot 0.5 H_2O$:

20 Calc'd: C, 55.48; H, 3.11; N, 3.60.
Found: C, 54.14; H, 3.06; N, 3.42.

Example 12

(E)-2-[2-Methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-nicotinic acid

Step 1) Preparation of (E)-2-[2-Methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-nicotinic acid methyl ester

30

To a solution of 2-aminonicotinic acid methyl ester (0.50 g, 3.26 mmol) and triethylamine (910 μ L, 6.52 mmol) in CH_2Cl_2 at 0°C was added via cannula (E)-3-[4-trifluoromethylphenyl]-2-propenoyl chloride (810 mg, 3.26 mmol), prepared in a manner identical to Step 3 of Example 1, as a solution in CH_2Cl_2 (5.0 mL). Upon 35 completed addition, the reaction mixture was allowed to warm to RT and stir for 2 h,

- 29 -

whereupon it was quenched with water (20 mL) and saturated NaHCO₃ (20 mL), then partitioned with EtOAc (20 mL). The aqueous phase was further extracted with EtOAc (3 x 20 mL), and the combined organic extracts were dried over MgSO₄, treated with Norite, concentrated and submitted to flash chromatography (elution with 75% EtOAc-hexanes) to afford 412 mg (35%) of a white solid.

Step 2) Preparation of (E)-2-[2-Methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-nicotinic acid

10 In a manner similar to Step 2 of Example 1 was prepared the title compound (61%) from the above methyl ester: mp 203.8-24.4°C; ¹H NMR (DMSO-d₆) δ 11.20 (br s, 1 H), 8.54 (dd, 1 H), 8.21 (dd, 1 H), 7.73 (ABq, 4 H), 7.45 (s, 1 H), 7.28 (dd, 1 H), 2.11 (d, 3 H); IR (KBr) 3301, 3079, 2994, 1686, 1607, 1560, 1454, 1411, 1387, 1261, 1203, 1189, 1168, 1148, 1047, 1016, 997, 892, 850, 777, 682 cm⁻¹; MS (m/z) 350 [M⁺].

Elemental analysis for C₁₇H₁₃F₃N₂O₃:

Calc'd: C, 58.29; H, 3.74; N, 8.00.
Found: C, 57.45; H, 3.56; N, 7.76.

20

Example 13

(E)-5-Methoxy-2-[2-methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid

25

In a manner similar to Step 3 of Example 1 was prepared the title compound (39%) from (E)-3-[4-trifluoromethylphenyl]-2-propenoic acid and 4-methoxy-antrhanilic acid: mp 207.2-208.0°C; ¹H NMR (DMSO-d₆) δ 13.80 (br s, 1 H), 11.54 (s, 1 H), 8.56 (d, 1 H), 7.73 (ABq, 4 H), 7.53 (s, 1 H), 7.50 (d, 1 H), 7.26 (dd, 1 H), 3.78 (s, 3 H), 2.17 (d, 3 H); IR (KBr) 3310, 3212, 3142, 3105, 2947, 2858, 1697, 1607, 1554, 1502, 1452, 1411, 1382, 1358, 1335, 1246, 1172, 1141, 1121, 1063, 855, 810, 751, 737, 691 cm⁻¹; MS (m/z) 379 [M⁺].

Elemental analysis for C₁₉H₁₆F₃NO₄:

35 Calc'd: C, 60.16; H, 4.25; N, 3.69.
Found: C, 60.31; H, 4.09; N, 3.65.

- 30 -

Example 14

(E)-2-[2-Methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid diethylcarbamoylmethyl ester

5

Step 1) Preparation of (E)-2-[2-Methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid sodium salt

10 In a manner similar to Step 4 of Example 1 (lithium hydride replaced by sodium hydride) was prepared the title intermediate (91%) from the corresponding carboxylic acid.

Step 2) Preparation of (E)-2-[2-Methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid diethylcarbamoylmethyl ester

To a homogeneous solution of the above carboxylate sodium salt (894 mg, 2.41 mmol) and sodium iodide (36 mg, 0.24 mmol) in DMF at RT under an inert atmosphere of N₂ was added dropwise N,N-diethyl-2-chloroacetamide (397 μ L, 2.89 mmol). Upon completed addition, the reaction mixture was heated to 50°C and stirred for 12 h, whereupon it was quenched with water (25 mL), then partitioned with EtOAc (50 mL). The aqueous phase was extracted again with EtOAc (50 mL); the combined organic phases were washed with 2% NaHCO₃ (2 x 25 mL), then diluted with hexanes (25 mL), and washed consecutively with water (3 x 25 mL) followed by brine (25 mL). Drying with MgSO₄, followed by concentration and recrystallization from ether-petroleum ether afforded 898 mg (74%) of a white solid: mp 76.4-77.2°C; ¹H NMR (CDCl₃) δ 11.46 (s, 1 H), 7.58-7.63 (m, 2 H), 7.57 (ABq, 4 H), 7.14 (ddd, 1 H), 4.99 (s, 2 H), 3.37 (dq, 4 H), 2.24 (d, 3 H), 1.21 (dt, 6 H); IR (KBr) ; MS (m/z).

30 Elemental analysis for $C_{24}H_{25}F_3N_2O_4$:

Calc'd: C, 62.33; H, 5.45; N, 6.06.

Found: C, 62.09, H, 5.30; N, 6.05.

- 31 -

Solid Phase Synthesis of Examples 15 through 264

To a suspension of Wang resin (0.7 g, 0.52 mmol) and triphenylphosphine (0.409 g, 1.56 mmol, 3 eq) in dichloromethane (4ml) was added N-chlorosuccinimide (0.394 g, 1.72 mmol, 3.3eq) at 0°C. The reaction was continued at 0°C for 5 hours and at room temperature for 10 hours. Then the solvent was removed by filtration and the resin was washed with dichloromethane (4x8 ml). Anthranilic acid, or appropriately substituted 1,2 or 1,3 aminobenzoic acid (5 eq), cesium carbonate (0.847 g, 2.6 mmol, 5 eq) and dimethylformamide (DMF) (6ml) were mixed with the above resin. After 60 hours of reaction, the solvent was filtrated, the resin was washed with water (2X5ml), DMF (4ml) and CH₂Cl₂(2X4ml). Dichloromethane (5ml), appropriately substituted diethylphosphonoacetic acid (3eq), diisopropyl carbodiimide (0.261 ml, 1.66 mmol, 3.3 eq) and dimethylaminopyridine (DMAP) (10mg) were reacted with the above resin for 20 h at room temperature. The reaction mixture was filtrated, washed with dichloromethane (5x4ml) and tetrahydrofuran (THF) (5ml). Lithium chloride (40 mg, 1.5 mmol, 3 eq), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (150 mg, 1.5 mmol, 3 eq) and THF (10ml) were mixed with the above resin for 1 hour, then appropriately substituted benzaldehyde (3 eq) was introduced at room temperature. After 18 hours, water (10ml) was added, the solvent was filtrated, then residue was washed with THF-H₂O (1:1, 10ml), water (10ml), THF (10ml), acetone (3x10 ml) and dichloromethane (3X10ml).

The above resin was treated with TFA (50% dichloromethane, 6 ml) for 1 hour, 25 the filtrate was evaporated *in vacuo* to give the crude product. Table A more fully describes the structures of Examples 15 through 264.

- 32 -

Example	R1	R2	R3	R4	R5	R6	R7	R8	R9	R10
15	2-CH ₃	H	H	COOH	H	H	H	H	H	H
16	2-CH ₃	H	H	COOH	H	H	H	H	CH ₃	H
17	2-CH ₃	H	H	H	COOH	H	H	H	H	H
18	2-CH ₃	H	H	H	COOH	H	H	H	CH ₃	H
19	2-CH ₃	H	H	COOH	H	H	H	H	5-Cl	H
20	2-CH ₃	H	H	COOH	H	H	H	5-Cl	CH ₃	H
21	2-CH ₃	H	H	H	COOH	H	H	6-Cl	H	H
22	2-CH ₃	H	H	H	COOH	H	H	6-Cl	CH ₃	H
23	2-CH ₃	H	H	COOH	H	H	H	4-Cl	H	H
24	2-CH ₃	H	H	COOH	H	H	H	4-Cl	CH ₃	H
25	3-CH ₃	H	H	COOH	H	H	H	H	H	H
26	3-CH ₃	H	H	COOH	H	H	H	H	CH ₃	H
27	3-CH ₃	H	H	H	COOH	H	H	H	H	H
28	3-CH ₃	H	H	H	COOH	H	H	H	CH ₃	H
29	3-CH ₃	H	H	COOH	H	H	H	5-Cl	H	H

Example	R1	R2	R3	R4	R5	R6	R7	R8	R9	R10
30	3-CH ₃	H	H	COOH	H	H	H	5-Cl	CH ₃	H
31	3-CH ₃	H	H	H	COOH	H	H	6-Cl	H	H
32	3-CH ₃	H	H	H	COOH	H	H	6-Cl	CH ₃	H
33	3-CH ₃	H	H	COOH	H	H	H	4-Cl	H	H
34	3-CH ₃	H	H	COOH	H	H	H	4-Cl	CH ₃	H
35	4-CH ₃	H	H	COOH	H	H	H	H	H	H
36	4-CH ₃	H	H	COOH	H	H	H	H	CH ₃	H
37	4-CH ₃	H	H	COOH	H	H	H	H	H	H
38	4-CH ₃	H	H	COOH	H	H	H	H	CH ₃	H
39	4-CH ₃	H	H	COOH	H	H	H	5-Cl	H	H
40	4-CH ₃	H	H	COOH	H	H	H	5-Cl	CH ₃	H
41	4-CH ₃	H	H	H	COOH	H	H	6-Cl	H	H
42	4-CH ₃	H	H	H	COOH	H	H	6-Cl	CH ₃	H
43	4-CH ₃	H	H	COOH	H	H	H	4-Cl	H	H
44	4-CH ₃	H	H	COOH	H	H	H	4-Cl	CH ₃	H

Example	R1	R2	R3	R4	R5	R6	R7	R8	R9	R10
45	2-F	H	H	COOH	H	H	H	H	H	H
46	2-F	H	H	COOH	H	H	H	CH3	H	H
47	2-F	H	H	H	COOH	H	H	H	H	H
48	2-F	H	H	H	COOH	H	H	H	CH3	H
49	2-F	H	H	COOH	H	H	H	5-Cl	H	H
50	2-F	H	H	COOH	H	H	H	5-Cl	CH3	H
51	2-F	H	H	H	COOH	H	H	6-Cl	H	H
52	2-F	H	H	H	COOH	H	H	6-Cl	CH3	H
53	2-F	H	H	COOH	H	H	H	4-Cl	H	H
54	2-F	H	H	COOH	H	H	H	4-Cl	CH3	H
55	3-F	H	H	COOH	H	H	H	H	CH3	H
56	3-F	H	H	COOH	H	H	H	H	CH3	H
57	3-F	H	H	H	COOH	H	H	H	H	H
58	3-F	H	H	H	COOH	H	H	H	CH3	H
59	3-F	H	H	COOH	H	H	H	5-Cl	H	H

Example	R1	R2	R3	R4	R5	R6	R7	R8	R9	R10
60	3-F	H	H	COOH	H	H	H	5-Cl	CH3	H
61	3-F	H	H	H	COOH	H	H	6-Cl	H	H
62	3-F	H	H	H	COOH	H	H	6-Cl	CH3	H
63	3-F	H	H	COOH	H	H	H	4-Cl	H	H
64	3-F	H	H	COOH	H	H	H	4-Cl	CH3	H
65	4-F	H	H	COOH	H	H	H	H	H	H
66	4-F	H	H	COOH	H	H	H	H	CH3	H
67	4-F	H	H	COOH	H	H	H	H	H	H
68	4-F	H	H	COOH	H	H	H	H	CH3	H
69	4-F	H	H	COOH	H	H	H	5-Cl	H	H
70	4-F	H	H	COOH	H	H	H	5-Cl	CH3	H
71	4-F	H	H	H	COOH	H	H	6-Cl	H	H
72	4-F	H	H	COOH	H	H	H	6-Cl	CH3	H
73	4-F	H	H	COOH	H	H	H	4-Cl	H	H
74	4-F	H	H	COOH	H	H	H	4-Cl	CH3	H

Example	R1	R2	R3	R4	R5	R6	R7	R8	R9	R10
75	2-Cl	H	H	COOH	H	H	H	H	H	H
76	2-Cl	H	H	COOH	H	H	H	H	CH3	H
77	2-Cl	H	H	COOH	H	H	H	H	H	H
78	2-Cl	H	H	COOH	H	H	H	H	CH3	H
79	2-Cl	H	H	COOH	H	H	H	5-Cl	H	H
80	2-Cl	H	H	COOH	H	H	H	5-Cl	CH3	H
81	2-Cl	H	H	COOH	H	H	6-Cl	H	H	
82	2-Cl	H	H	COOH	H	H	6-Cl	CH3	H	
83	2-Cl	H	H	COOH	H	H	4-Cl	H	H	
84	2-Cl	H	H	COOH	H	H	4-Cl	CH3	H	
85	3-Cl	H	H	COOH	H	H	H	H	CH3	H
86	3-Cl	H	H	COOH	H	H	H	H	CH3	H
87	3-Cl	H	H	COOH	H	H	H	H	H	H
88	3-Cl	H	H	COOH	H	H	H	H	CH3	H
89	3-Cl	H	H	COOH	H	H	H	5-Cl	H	H

Example	R1	R2	R3	R4	R5	R6	R7	R8	R9	R10
90	3-Cl	H	H	COOH	H	H	H	5-Cl	CH3	H
91	3-Cl	H	H	H	COOH	H	H	6-Cl	H	H
92	3-Cl	H	H	H	COOH	H	H	6-Cl	CH3	H
93	3-Cl	H	H	COOH	H	H	H	4-Cl	H	H
94	3-Cl	H	H	COOH	H	H	H	4-Cl	CH3	H
95	2-Br	H	H	COOH	H	H	H	H	H	H
96	2-Br	H	H	COOH	H	H	H	H	CH3	H
97	2-Br	H	H	H	COOH	H	H	H	H	H
98	2-Br	H	H	H	COOH	H	H	H	CH3	H
99	2-Br	H	H	COOH	H	H	H	5-Cl	H	H
100	2-Br	H	H	COOH	H	H	H	5-Cl	CH3	H
101	2-Br	H	H	H	COOH	H	H	6-Cl	H	H
102	2-Br	H	H	H	COOH	H	H	6-Cl	CH3	H
103	2-Br	H	H	COOH	H	H	H	4-Cl	H	H
104	2-Br	H	H	COOH	H	H	H	4-Cl	CH3	H

Example	R1	R2	R3	R4	R5	R6	R7	R8	R9	R10
105	3-Br	H	H	COOH	H	H	H	H	H	H
106	3-Br	H	H	COOH	H	H	H	H	CH ₃	H
107	3-Br	H	H	H	COOH	H	H	H	H	H
108	3-Br	H	H	H	COOH	H	H	H	CH ₃	H
109	3-Br	H	H	COOH	H	H	H	5-Cl	H	H
110	3-Br	H	H	COOH	H	H	H	5-Cl	CH ₃	H
111	3-Br	H	H	H	COOH	H	H	6-Cl	H	H
112	3-Br	H	H	H	COOH	H	H	6-Cl	CH ₃	H
113	3-Br	H	H	COOH	H	H	H	4-Cl	H	H
114	3-Br	H	H	COOH	H	H	H	4-Cl	CH ₃	H
115	2-CF ₃	H	H	COOH	H	H	H	H	CH ₃	H
116	2-CF ₃	H	H	H	COOH	H	H	H	H	H
117	2-CF ₃	H	H	H	COOH	H	H	H	H	H
118	2-CF ₃	H	H	H	COOH	H	H	H	CH ₃	H
119	2-CF ₃	H	H	COOH	H	H	H	5-Cl	H	H

- 39 -

Example	R1	R2	R3	R4	R5	R6	R7	R8	R9	R10
120	2-CF ₃	H	H	COOH	H	H	H	5-Cl	CH ₃	H
121	2-CF ₃	H	H	H	COOH	H	H	6-Cl	H	H
122	2-CF ₃	H	H	H	COOH	H	H	6-Cl	CH ₃	H
123	2-CF ₃	H	H	COOH	H	H	H	4-Cl	H	H
124	2-CF ₃	H	H	COOH	H	H	H	4-Cl	CH ₃	H
125	3-CF ₃	H	H	COOH	H	H	H	4-Cl	H	H
126	3-CF ₃	H	H	COOH	H	H	H	H	CH ₃	H
127	3-CF ₃	H	H	COOH	H	H	H	H	H	H
128	3-CF ₃	H	H	COOH	H	H	H	H	CH ₃	H
129	3-CF ₃	H	H	COOH	H	H	H	5-Cl	H	H
130	3-CF ₃	H	H	COOH	H	H	H	5-Cl	CH ₃	H
131	3-CF ₃	H	H	H	COOH	H	H	6-Cl	H	H
132	3-CF ₃	H	H	H	COOH	H	H	6-Cl	CH ₃	H
133	3-CF ₃	H	H	COOH	H	H	H	4-Cl	H	H
134	3-CF ₃	H	H	COOH	H	H	H	4-Cl	CH ₃	H

Example	R1	R2	R3	R4	R5	R6	R7	R8	R9	R10
135	4-CF3	H	H	COOH	H	H	H	H	H	H
136	4-CF3	H	H	COOH	H	H	H	H	CH3	H
137	4-CF3	H	H	COOH	H	H	H	H	H	H
138	4-CF3	H	H	COOH	H	H	H	H	CH3	H
139	4-CF3	H	H	COOH	H	H	H	5-Cl	H	H
140	4-CF3	H	H	COOH	H	H	H	5-Cl	CH3	H
141	4-CF3	H	H	COOH	H	H	H	6-Cl	H	H
142	4-CF3	H	H	COOH	H	H	H	6-Cl	CH3	H
143	4-CF3	H	H	COOH	H	H	H	4-Cl	H	H
144	4-CF3	H	H	COOH	H	H	H	4-Cl	CH3	H
145	H	H	H	COOH	H	H	H	H	H	H
146	H	H	H	COOH	H	H	H	CH3	H	H
147	H	H	H	COOH	H	H	H	H	H	H
148	H	H	H	COOH	H	H	H	CH3	H	H
149	H	H	H	COOH	H	H	H	5-Cl	H	H

Example	R1	R2	R3	R4	R5	R6	R7	R8	R9	R10
150	H	H	H	COOH	H	H	H	5-Cl	CH3	H
151	H	H	H	H	COOH	H	H	6-Cl	H	H
152	H	H	H	H	COOH	H	H	6-Cl	CH3	H
153	H	H	H	COOH	H	H	H	4-Cl	H	H
154	H	H	H	COOH	H	H	H	4-Cl	CH3	H
155	4-Cl	H	H	COOH	H	H	H	4-Cl	H	H
156	4-Cl	H	H	COOH	H	H	H	H	CH3	H
157	4-Cl	H	H	COOH	H	H	H	H	H	H
158	4-Cl	H	H	COOH	H	H	H	H	CH3	H
159	4-Cl	H	H	COOH	H	H	H	5-Cl	H	H
160	4-Cl	H	H	COOH	H	H	H	5-Cl	CH3	H
161	4-Cl	H	H	H	COOH	H	H	6-Cl	H	H
162	4-Cl	H	H	H	COOH	H	H	6-Cl	CH3	H
163	4-Cl	H	H	COOH	H	H	H	4-Cl	H	H
164	4-Cl	H	H	COOH	H	H	H	4-Cl	CH3	H

Example	R1	R2	R3	R4	R5	R6	R7	R8	R9	R10
165	4-Br	H	H	COOH	H	H	H	H	H	H
166	4-Br	H	H	COOH	H	H	H	H	CH3	H
167	4-Br	H	H	H	COOH	H	H	H	H	H
168	4-Br	H	H	H	COOH	H	H	H	CH3	H
169	4-Br	H	H	COOH	H	H	H	5-Cl	H	H
170	4-Br	H	H	COOH	H	H	H	5-Cl	CH3	H
171	4-Br	H	H	H	COOH	H	H	6-Cl	H	H
172	4-Br	H	H	H	COOH	H	H	6-Cl	CH3	H
173	4-Br	H	H	COOH	H	H	H	4-Cl	H	H
174	4-Br	H	H	COOH	H	H	H	4-Cl	CH3	H
175	2-MeO	H	H	COOH	H	H	H	H	H	H
176	2-MeO	H	H	COOH	H	H	H	H	CH3	H
177	2-MeO	H	H	H	COOH	H	H	H	H	H
178	2-MeO	H	H	H	COOH	H	H	H	CH3	H
179	2-MeO	H	H	COOH	H	H	H	5-Cl	H	H

Example	R1	R2	R3	R4	R5	R6	R7	R8	R9	R10
180	2-MeO	H	H	COOH	H	H	H	5-Cl	CH3	H
181	2-MeO	H	H	H	COOH	H	H	6-Cl	H	H
182	2-MeO	H	H	H	COOH	H	H	6-Cl	CH3	H
183	2-MeO	H	H	COOH	H	H	H	4-Cl	H	H
184	2-MeO	H	H	COOH	H	H	H	4-Cl	CH3	H
185	3-MeO	H	H	COOH	H	H	H	H	H	H
186	3-MeO	H	H	COOH	H	H	H	H	CH3	H
187	3-MeO	H	H	H	COOH	H	H	H	H	H
188	3-MeO	H	H	H	COOH	H	H	H	CH3	H
189	3-MeO	H	H	COOH	H	H	H	5-Cl	H	H
190	3-MeO	H	H	COOH	H	H	H	5-Cl	CH3	H
191	3-MeO	H	H	COOH	H	H	H	6-Cl	H	H
192	3-MeO	H	H	H	COOH	H	H	6-Cl	CH3	H
193	3-MeO	H	H	COOH	H	H	H	4-Cl	H	H
194	3-MeO	H	H	COOH	H	H	H	4-Cl	CH3	H

Example	R1	R2	R3	R4	R5	R6	R7	R8	R9	R10
195	4-MeO	H	H	COOH	H	H	H	H	H	H
196	4-MeO	H	H	COOH	H	H	H	H	CH3	H
197	4-MeO	H	H	COOH	H	H	H	H	H	H
198	4-MeO	H	H	COOH	H	H	H	H	CH3	H
199	4-MeO	H	H	COOH	H	H	H	5-Cl	H	H
200	4-MeO	H	H	COOH	H	H	H	5-Cl	CH3	H
201	4-MeO	H	H	COOH	H	H	H	6-Cl	H	H
202	4-MeO	H	H	COOH	H	H	H	6-Cl	CH3	H
203	4-MeO	H	H	COOH	H	H	H	4-Cl	H	H
204	4-MeO	H	H	COOH	H	H	H	4-Cl	CH3	H
205	2-NO2	H	H	COOH	H	H	H	H	H	H
206	2-NO2	H	H	COOH	H	H	H	H	CH3	H
207	2-NO2	H	H	COOH	H	H	H	H	H	H
208	2-NO2	H	H	COOH	H	H	H	H	CH3	H
209	2-NO2	H	H	COOH	H	H	H	5-Cl	H	H

- 45 -

Example	R1	R2	R3	R4	R5	R6	R7	R8	R9	R10
210	2-NO2	H	H	COOH	H	H	H	5-Cl	CH3	H
211	2-NO2	H	H	H	COOH	H	H	6-Cl	H	H
212	2-NO2	H	H	H	COOH	H	H	6-Cl	CH3	H
213	2-NO2	H	H	COOH	H	H	H	4-Cl	H	H
214	2-NO2	H	H	COOH	H	H	H	4-Cl	CH3	H
215	3-NO2	H	H	COOH	H	H	H	H	H	H
216	3-NO2	H	H	COOH	H	H	H	H	CH3	H
217	3-NO2	H	H	COOH	H	H	H	H	H	H
218	3-NO2	H	H	H	COOH	H	H	H	CH3	H
219	3-NO2	H	H	COOH	H	H	H	5-Cl	H	H
220	3-NO2	H	H	COOH	H	H	H	5-Cl	CH3	H
221	3-NO2	H	H	COOH	H	H	H	6-Cl	H	H
222	3-NO2	H	H	COOH	H	H	H	6-Cl	CH3	H
223	3-NO2	H	H	COOH	H	H	H	4-Cl	H	H
224	3-NO2	H	H	COOH	H	H	H	4-Cl	CH3	H

- 46 -

Example	R1	R2	R3	R4	R5	R6	R7	R8	R9	R10
225	4-NO ₂	H	H	COOH	H	H	H	H	H	H
226	4-NO ₂	H	H	COOH	H	H	H	H	CH ₃	H
227	4-NO ₂	H	H	H	COOH	H	H	H	H	H
228	4-NO ₂	H	H	H	COOH	H	H	H	CH ₃	H
229	4-NO ₂	H	H	COOH	H	H	H	5-Cl	H	H
230	4-NO ₂	H	H	COOH	H	H	H	5-Cl	CH ₃	H
231	4-NO ₂	H	H	H	COOH	H	H	6-Cl	H	H
232	4-NO ₂	H	H	H	COOH	H	H	6-Cl	CH ₃	H
233	4-NO ₂	H	H	COOH	H	H	H	4-Cl	H	H
234	4-NO ₂	H	H	COOH	H	H	H	4-Cl	CH ₃	H
235	4-N(CH ₃) ₂	H	H	COOH	H	H	H	H	H	H
236	4-N(CH ₃) ₂	H	H	COOH	H	H	H	H	CH ₃	H
237	4-N(CH ₃) ₂	H	H	COOH	H	H	H	H	H	H
238	4-N(CH ₃) ₂	H	H	H	COOH	H	H	H	CH ₃	H
239	4-N(CH ₃) ₂	H	H	COOH	H	H	H	5-Cl	H	H

Example	R1	R2	R3	R4	R5	R6	R7	R8	R9	R10
240	4N(CH ₃) ₂	H	H	COOH	H	H	5-Cl	CH ₃	H	
241	4N(CH ₃) ₂	H	H	H	COOH	H	H	6-Cl	H	H
242	4N(CH ₃) ₂	H	H	H	COOH	H	H	6-Cl	CH ₃	H
243	4N(CH ₃) ₂	H	H	COOH	H	H	H	4-Cl	H	H
244	4N(CH ₃) ₂	H	H	COOH	H	H	4-Cl	CH ₃	H	
245	2-Cl	4-Cl	H	COOH	H	H	H	H	H	
246	2-Cl	4-Cl	H	COOH	H	H	H	H	CH ₃	H
247	2-Cl	4-Cl	H	H	COOH	H	H	H	H	H
248	2-Cl	4-Cl	H	H	COOH	H	H	H	CH ₃	H
249	2-Cl	4-Cl	H	COOH	H	H	H	5-Cl	H	H
250	2-Cl	4-Cl	H	COOH	H	H	H	5-Cl	CH ₃	H
251	2-Cl	4-Cl	H	H	COOH	H	H	6-Cl	H	H
252	2-Cl	4-Cl	H	H	COOH	H	H	6-Cl	CH ₃	H
253	2-Cl	4-Cl	H	COOH	H	H	H	4-Cl	H	H
254	2-Cl	4-Cl	H	COOH	H	H	H	4-Cl	CH ₃	H

- 49 -

Smooth Muscle Relaxing Activity

The smooth muscle relaxing activity of the compounds of this invention was established in accordance with standard pharmaceutically accepted test procedures with representative compounds as follows:

- 5 Sprague-Dawley rats (150-200 g) are rendered unconscious by CO₂ asphyxiation and then euthanized by cervical dislocation. The bladder is removed into warm (37 deg.C) physiological salt solution (PSS) of the following composition (mM): NaCl, 118.4; KCl, 4.7; CaCl₂, 2.5; MgSO₄, 4.7; H₂O, 1.2; NaHCO₃, 24.9; KH₂PO₄, 1.2; glucose, 11.1; EDTA, 0.023; gassed with 95% O₂; 2/5% CO₂; pH 7.4.
- 10 The bladder is opened and then cut into strips 1-2 mm in width and 7-10 mm in length. The strips are subsequently suspended in a 10 mL tissue bath under an initial resting tension of 1.5 g. The strips are held in place by two surgical clips one of which is attached to a fixed hook while the other is attached to an isometric force transducer. The preparations, which usually exhibit small spontaneous contractions, are allowed to
- 15 recover for a period of 1 hour prior to a challenge with 0.1 μ M carbachol. The carbachol is then washed out and the tissue allowed to relax to its resting level of activity. Following a further 30 min period of recovery an additional 15 mM KCl are introduced into the tissue bath. This increase in KCl concentration results in a large increase in the amplitude of spontaneous contractions (and initiation of contractions in
- 20 previously quiescent strips) superimposed upon a small increase in basal tone. Following stabilization of this enhanced level of contractile activity, incremental increases in the concentration of test compound or vehicle are introduced into the tissue bath. Contractile activity is measured for each compound or vehicle concentration during the last minute of a 30 minute challenge.
- 25
- 30 The isometric force developed by the bladder strips is measured using a concentration required to elicit 50% inhibition of pre-drug contractile activity (IC₅₀ concentration) and is calculated from this concentration-response curve. The maximum percentage inhibition of contractile activity evoked by a test compound is also recorded for concentrations of test compound less than or equal to 30 μ M.

- 50 -

The results of this study are shown in Table I.

Table I

5

Inhibition of Contractions in Isolated Rat Bladder Strips and Indication of Selectivity

10

Example #	n	IC ₅₀ /μM Bladder(B)	n	IC ₅₀ /μM Aorta(A)	IC ₅₀ (A)/ IC ₅₀ (B)
1, Step 3	4	3.7±2.1	5	61.2±9.2	16.5
1, Step 4	6	1.07±0.37	6	41.9±8.4	39.6
2	2	14.1±1.77	4	118.2±27.6	8.4
3	4	4.9±2.6	3	53.5±7	11
4	7	3.37±0.59	3	39.5±12	11.7
5	6	5.3±2.8	7	146±49	27.5
6	5	18.1±4.2	--	--	--
7	4	7.4±4	--	--	--
8	4	1.18±0.45	3	4.23±0.66	3.58
9	2	0.52±0.24	3	2.76±1.63	5.31
10	4	1.44±0.85	3	6.93±2.4	4.81
11	6	3.45±0.75	--	--	--
12	3	11.4±3.8	--	--	--
13	2	9.6±7.4	--	--	--
14	3	10.8±0.6	--	--	--
14	3	I=35.6±5%*	--	--	--
Tranilast [®] §	2	14.4±4.5	5	15.59±8.96	1.08

§ Tranilast is (E)-2-[3-(3,4-Dimethoxy-phenyl)-acryloylamino]-benzoic acid.

*Percent inhibition at 30 μM

15

In addition, we tested the ability of compounds to inhibit the hyperactivity of hypertrophied bladder (detrusor) smooth muscle in conscious female rats with hypertrophied bladders and thereby alleviate urinary incontinence in rats according to the following protocol described by Malmgren (A. Malmgren, K.E. Andersson, C. Sjogren, P.O. Andersson, Effects of Pinacidil and Cromakalim (BRL 34915) on Bladder Function in Rats with Detrusor Instability, *J. Urol.* 142:1134, 1989.):

25

- 51 -

Female Sprague-Dawley rats, ranging in weight from 190-210g are used. Up to 25 animals are prepared each time. After development of bladder hypertrophy 4-8 animals are used per test.

5 Compounds are dissolved in PEG-200 and administered by gastric gavage or intraveneously in a volume of 5 mL/kg. For primary screening all drugs are administered at the arbitrary dose of 10 mg/kg p.o. to groups of 4 rats.

10 The animals are anesthetized with halothane. Through a midline incision the bladder and urethra are exposed and a ligature of 4-0 silk is tied around the proximal urethra in the presence of a stainless steel rod (1 mm diameter) to produce a partial occlusion. The rod is then removed. The abdominal region is closed using surgical staples and each rat receives 150,000 units of bicillin C-R. The animals are allowed six weeks to develop sufficient bladder hypertrophy. After six weeks, the ligature is removed under 15 halothane anesthesia and a catheter (PE 60) with a cuff is placed in the dome of the bladder and secured with a purse string suture. The catheter is tunneled under the skin and exteriorized through an opening in the back of the neck. The abdominal incision is sutured and the free end of the catheter sealed. In order to prevent infections the rats receive an injection of bicillin C-R (150000 units/rat). Two days later the animals are used in 20 cystometrical evaluations. The animals are placed in the metabolic cages and the catheter is attached (using a "T" connector) to a Statham pressure transducer (Model P23Db) and to a Harvard infusion pump. A plastic beaker attached to a force displacement transducer (Grass FTO3) is placed under the rat's cage to collect and record urine volume. Animals are allowed 15-30 min to rest before the saline infusion (20 mL/hr for 20 minutes) is started 25 for the first cystometry period. Two hours after the first cystometry period, the rats are dosed with the vehicle or the test compound and one hour later a second cystometry is performed.

The following urodynamic variables are recorded:

30 Basal bladder pressure = the lowest bladder pressure during cystometry

Threshold pressure = bladder pressure immediately prior to micturition

35 Micturition volume = volume expelled

- 52 -

Micturition pressure = peak pressure during voiding
 Spontaneous activity = mean amplitude of bladder pressure fluctuations during filling

5 Presentation of results:

The mean value of each variable is calculated before and after compound administration. For each compound the changes in the variables measured are compared to the values obtained before treatment and expressed as percent inhibition.

10 The data are also subjected to 2-way analysis of variance to determine significant ($p<0.05$) changes in the variable measured.

Criteria for Activity:

15 The most characteristic finding in this rat model is spontaneous bladder contractions which develop during filling. The compounds which inhibit spontaneous contractions by at least 50% at 10 mg/kg p.o. or i.v. (arbitrary chosen dose) are considered active.

The results of this study are shown in Table II

20

Table II
Inhibition of Spontaneous Contractions In Vivo

Compound	# of animals	dose mg/kg (i.v.)	% Red (F)*
Example 9	10	30	-71±6

* percent reduction in the total number of spontaneous contractions in the hypertrophied
 25 rat bladder model

Potassium Channel Activation

Potassium channel activation by compounds of the present invention was
 30 established by examining the effect of the compound of Example 1 on calcium-dependent large conductance potassium channels (maxi K^+) as follows:

Rat detrusor cells were isolated in a manner previously described for guinea-pig detrusor (Sheldon and Argentieri, 1995). Male Sprague-Dawley rats (200-400 grams) 35 were euthanized by CO_2 inhalation and exsanguination. Their urinary bladders were

- 53 -

rapidly removed and placed in 37°C physiological solution with the following composition (mM): Na glutamate (80.0), NaCl (54.7), KCl (5.0), NaHCO₃ (25.0), MgCl₂•2H₂O (2.5), D-glucose (11.8) and CaCl₂ (0.2) gassed with CO₂-O₂, 95%/5% for a final pH of 7.4. The dome of the bladder was isolated from the trigon region and
5 the mucosa was removed. This tissue was then cut into 2-3 mm wide strips and placed in fresh buffer for 1 hour. Tissues were then transferred into 10.0 ml of an isolation buffer containing the above composition plus collagenase type VIII (1.0 mg/ml) and pronase (0.25 mg/ml). After 10 minutes the isolation buffer was replaced with fresh isolation buffer for an additional 10 min. The tissue was then washed 3 times in fresh
10 collagenase and pronase free solution and stored at room temperature until studied. Cells for study were prepared by triturating 1-2 pieces of detrusor tissue in 2 mL of fresh isolation buffer for 5 minutes with a polished Pasteur pipette, (tip diameter ~1.5 ml) attached to a modified Harvard Respirator pump (Harvard Apparatus, Southnatic, MA) at a rate of 20x/min. with an approximate volume of 5 mL. Cells were then placed
15 on a microscope stage in a temperature regulated tissue bath at 32.50 C and continually superfused with physiological salt solution (PSS) that contained the following (mM): NaCl (118.4), KCl (4.7), CaCl₂ (2.5), MgSO₄ (1.2), KH₂PO₄ (1.2), NaHCO₃ (24.9) and D-glucose (11.1) gassed with CO₂-O₂, 95%/5% to achieve a pH of 7.4.

20 Single cell recordings were performed with a List-Medical EPC-7 patch clamp amplifier (Adams & List Assoc., Westbury, NY). Pipette electrodes had tip resistances of 2-4 MΩ and were filled with the following composition (mM): KCl (126.0), MgCl₂•6H₂O (4.5), ATP Mg salt (4.0), GTP tris salt (0.3), creatine PO₄ (14.0), D-glucose (9.0), EGTA (9.0), HEPES (9.0). The pH was adjusted to 7.4 with KOH.
25 Signals were acquired (3 kHz high frequency cut-off) using a 586-based personal computer and pClamp (Axon Instruments, Foster City, Ca) software.

Whole cell recordings were made using broken patch assess. Currents were evoked using either voltage steps (Vh=-50; Vt=-60 to 40 mV) or voltage ramps (-60 to 40 mV at 3.3 mV/sec.). After stability was achieved control currents were recorded.
30 Next, WAY-131354-A (10 μM) was added to the superfusate. Currents were recorded for 5 to 10 minutes or until compound effects reached steady state. This was followed either by washout or addition of glyburide (5 μM) to the superfusate.

- 54 -

Results:

All cells exposed to Example 1 (dissolved in DMSO and further diluted in PSS) responded with an increase in outward current that was reversible upon washout (Figure 1). Exposure to the sulfonyl urea glyburide had no effect (data not shown).

5 Previous studies have shown that this current is iberiotoxin sensitive which is a hallmark of the maxi K⁺ channel. It is concluded therefore, that the compound of Example 1 is capable of activating the maxi K⁺ current in isolated rat bladder cells consistent with its ability to inhibit KCl-induced contractions of intact tissue in vitro.

10

Chloride Channel Blockade

The ability of compounds of the present invention to act as chloride channel blockers was established as follows.

15 Normal human bronchial epithelial cells (NHBE) were commercially available from Clonetics Corporation (San Diego, CA) and bladder cells were isolated from rat bladder.

The normal external solution contained (in mM): N-methyl d-Glucamine chloride (NMDGCl). 140, MgCl₂ 2, CaCl₂ 2 and 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid (HEPES) 10. The normal pipette solution contained (in mM): NMDGCl. 125, HEPES 10, MgCl₂ 2, ethyleneglycolbis(oxonitrilo)tetraacetate (EGTA) 2, 20 and ATP_{Mg} 5, the pH adjusted to 7.3 with TRIS. To identify the leak conductance from depolarization, internal Cl⁻ ion concentration was reduced to 40 mM using glutamic acid (E_{Cl} approximately -31 mV according Nernst equation). The osmolarity for standard external solution was about 280 mOsm. Hypotonic solutions were obtained by diluting the normal external solution with distilled water.

25 The whole cell voltage clamp recording techniques were utilized to record membrane ionic currents. The volume of the recording chamber was 1 ml and the rate of superfusion was 4 ml/min. Membrane currents were recorded using an Axopatch 200A Patch Clamp Amplifier (Axon Instruments, Inc., Foster City, CA). Under voltage clamp conditions, the cells were stimulated at 0.2 Hz to be sure channels were 30 completely recovered between two voltage steps. Membrane currents were generated by following three protocols: 1) For monitoring; V_h (holding potential) = -30 mV, V_c (clamp potential) = 60 mV and T_c (clamp time) = 1 s. 2) For ramp test; V_h = -30 mV, V_{ramp} (ramp potential range) = from -100 to 100 mV, T_{ramp} = 3 s. 3). For current-voltage curve (I-V); V_h = -30 mV, V_c = from -100 to 100 mV with 10 mV step and T_c 35 = 1 s.

- 55 -

The effects of compounds of Formula I on chloride currents was evaluated in normal human broncholar epithelial cells (NHBE) and guinea pig bladder and are summarized in the table below:

Test	Preparation	Type of I_{Cl}	% blockade	% blockade	Washable
			10 μM	20 μM	
1	NHBE	CFTR	23%	80%	Yes
2	NHBE	CFTR		96%	Yes
3	Bladder	Swelling		67%	Yes
4	NHBE	CFTR		71%	n/a
5	NHBE	CFTR		79%	Yes
6	NHBE	CFTR		98%	Yes
			0.82 +- 0.05; n=6		

5 CFTR=cystic fibrosis transregulatory chloride channel

Figure 2 shows that Example 1 inhibited swelling induced chloride channel current on guinea pig bladder cell. A: current traces from -100 to 60 mV were recorded in the isotonic, low osmolarity (210 mOsm) and after application of 20 μM Example 1 in 10 same cell. Example 1 significantly reduced swelling induced chloride current. Panel B is four superimposed ramp test traces recorded in the presence of control, hypotonic, Example 1 and washout solutions. The C panel depicts the time course of the effect of Example 1 on $I_{Cl,swelling}$ at 60 mV monitored from the same cell. The figure shows that $I_{Cl,swelling}$ reached a steady state within 15 min following the addition of 210 mOsm 15 solution and with a 67 % block in presence of 20 μM Example 1.


Hence, the compounds of this invention have a pronounced effect on smooth muscle contractility and are useful in the treatment of gastrointestinal, cardiovascular, metabolic and central nervous system disorders such as urinary incontinence, irritable bladder and bowel disease, asthma, hypertension, stroke, cystic fibrosis, cardiac arrhythmias, peripheral vascular disease, congestive heart failure, anxiety neurodegenerative disease. and similar diseases as mentioned above, which are amenable to treatment with potassium channel activating and/or chloride channel blocking compounds by administration, orally, parenterally, or by aspiration to a patient in need thereof.

- 56 -

CLAIMS

What is claimed is:

5 1. A compound having the formula:



10

(I)

wherein:

R₁, R₂ and R₃ are, independently, hydrogen, cyano, C₁₋₁₀ perhaloalkoxy, sulfonic acid, C₁₋₁₀ alkylsulfonyl, C₆₋₁₂ arylsulfonyl, C₆₋₁₂ aralkylsulfonyl, C₁₋₁₀ alkylsulfinyl, C₆₋₁₂ arylsulfinyl, C₆₋₁₂ aralkylsulfinyl, sulfamoyl, C₁₋₁₀ alkylsulfamido, C₆₋₁₂ arylsulfamido, C₁₋₁₀ alkanoyl, C₆₋₁₂ aryloyl, C₆₋₁₂ aralkanoyl, amino, C₁₋₁₀ alkylamino, C₂₋₁₀ dialkylamino, C₆₋₁₂ aralkylamino, C₆₋₁₂ arylamino, carboxamido, C₁₋₁₀ alkylcarboxamido, C₆₋₁₂ arylcarboxamido, C₁₋₁₀ perhaloalkyl; with the provisos: (1) that R₁, R₂ and R₃ may not all simultaneously be hydrogen, and (2) when R₁ and R₂ are hydrogen, R₃ may not be *meta*-CF₃;

R₄, R₅, R₆, R₇ and R₈ are, independently, hydrogen, COOR₁₅, halogen, nitro, cyano, C₁₋₁₀ alkoxy, C₁₋₁₀ haloalkoxy, sulfonic acid, C₁₋₁₀ alkylsulfonyl, C₆₋₁₂ arylsulfonyl, C₆₋₁₂ aralkylsulfonyl, C₁₋₁₀ alkylsulfinyl, C₆₋₁₂ arylsulfinyl, C₆₋₁₂ aralkylsulfinyl, sulfamoyl, C₁₋₁₀ alkylsulfamido, C₆₋₁₂ arylsulfamido, C₁₋₁₀ alkanoyl, C₆₋₁₂ aryloyl, C₆₋₁₂ aralkanoyl, amino, C₁₋₁₀ alkylamino, C₂₋₁₀ dialkylamino, C₆₋₁₂ aralkylamino, C₆₋₁₂ arylamino, carboxamido, C₁₋₁₀ alkylcarboxamido, C₆₋₁₂ arylcarboxamido, C₁₋₁₀ haloalkyl, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₆₋₁₂ aryl, and C₆₋₁₂ aralkyl, with the proviso that at least one of R₄ and R₅ is COOR₁₅;

R₉ is hydrogen, C₁₋₁₀ alkyl and C₁₋₁₀ haloalkyl;

- 57 -

R_{10} is hydrogen, C_{1-10} alkyl, C_{1-10} haloalkyl, or C_{2-12} alkylidene;
 R_{15} is hydrogen, metal cation, acetyl amido, alkoxyacetoyl or a related moiety
 which delivers the carboxylate in vivo;
 the dotted line is an optional double bond; with the proviso that when R_{10} is an
 5 alkylidene moiety, the bond is absent; and
 W is nitrogen or carbon bearing a hydrogen, or R_4 , R_5 or R_6 as hereinbefore
 defined; or pharmaceutical salts thereof.

10 2. A compound of claim 1 wherein R_{15} is selected from the group
 consisting of hydrogen, a metal cation, a moiety selected from:



15 wherein R_{11} , R_{12} , R_{13} , and R_{14} are, independently, hydrogen, C_{1-10} alkyl, C_{6-12} aryl, or C_{2-12} aralkyl.

20 3. A compound of claim 1 wherein W is carbon bearing a hydrogen.

4. A compound of claim 1 wherein W is NH_2 .

25 5. A compound of claim 1 wherein at least one of R_1 , R_2 and R_3 is C_{1-6} perhaloalkyl.

6. A compound of claim 1 wherein at least one of R_1 , R_2 and R_3 is trifluoromethyl.

25 7. A compound of claim 1 wherein one of R_1 , R_2 and R_3 is 4-trifluoromethyl.

30 8. A compound of claim 1 wherein at least one of R_6 , R_7 and R_8 is a halogen.

9. A compound of claim 1 wherein one of R_6 , R_7 and R_8 is 4-chloro.

10. A compound of claim 1 wherein R_4 is $COOR_{15}$.

- 58 -

11. A compound of claim 1 wherein R_4 is COOH.
- 5 12. A compound of claim 1 wherein R_{10} is alkylidene.
13. A compound of claim 1 wherein R_9 is C_{1-6} alkyl.
- 10 14. A compound of claim 1 wherein R_9 is methyl.
- 15 16. A compound of claim 1 which is (E)-2-[2-Methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid lithium salt or a pharmaceutical salt thereof.
17. A compound of claim 1 which is 2-[3-(4-Trifluoromethyl-phenyl)propionyl-amino]-benzoic acid or a pharmaceutical salt thereof.
- 20 18. A compound of claim 1 which is (E)-2-[3[(4-Trifluoromethyl-phenyl)acryloyl-amino]-benzoic acid or a pharmaceutical salt thereof.
19. A compound of claim 1 which is (E)-2-[3[(4-Trifluoromethyl-phenyl)-acryloylamino]-benzoic acid lithium salt hemihydrate or a pharmaceutical salt thereof.
- 25 20. A compound of claim 1 which is 2-[3-(4-Trifluoromethyl-phenyl)-but-3-enoylamino]-benzoic acid or a pharmaceutical salt thereof.
21. A compound of claim 1 which is (E)-2-[3-(4-Trifluoromethyl-phenyl)-but-2-enoylamino]-benzoic acid sodium salt or a pharmaceutical salt thereof.
- 30 22. A compound of claim 1 which is (E)-5-Chloro-2-[2-methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid or a pharmaceutical salt thereof.
- 35 23. A compound of claim 1 which is (E)-5-Chloro-2-[2-methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid lithium salt hemihydrate or a pharmaceutical salt thereof.

- 59 -

24. A compound of claim 1 which is (E)-4-Chloro-2-[2-methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid or a pharmaceutical salt thereof.


5 25. A compound of claim 1 which is (E)-4-Chloro-2-[2-methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid lithium salt hemihydrate or a pharmaceutical salt thereof.

10 26. A compound of claim 1 which is (E)-2-[2-Methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-nicotinic acid or a pharmaceutical salt thereof.

27. A compound of claim 1 which is (E)-5-Methoxy-2-[2-methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid or a pharmaceutical salt thereof.

15 28. A compound of claim 1 which is (E)-2-[2-Methyl-3-(4-trifluoromethyl-phenyl)-acryloylamino]-benzoic acid diethylcarbamoylmethyl ester or a pharmaceutical salt thereof.

20 29. A pharmaceutical composition comprising a compound having the formula:



(I)

25

wherein:

30 R_1 , R_2 and R_3 are, independently, hydrogen, cyano, C_{1-10} perhaloalkoxy, sulfonic acid, C_{1-10} alkylsulfonyl, C_{6-12} arylsulfonyl, C_{6-12} aralkylsulfonyl, C_{1-10} alkylsulfinyl, C_{6-12} arylsulfinyl, C_{6-12} aralkylsulfinyl, sulfamoyl, C_{1-10} alkylsulfamido, C_{6-12} arylsulfamido, C_{1-10} alkanoyl, C_{6-12} aryloyl, C_{6-12} aralkanoyl, amino, C_{1-10} alkylamino, C_{2-10} dialkylamino, C_{6-12} aralkylamino,

- 60 -

C_{6-12} arylamino, carboxamido, C_{1-10} alkylcarboxamido, C_{6-12} arylcarboxamido, C_{1-10} perhaloalkyl; with the provisos: (1) that R_1 , R_2 and R_3 may not all simultaneously be hydrogen, and (2) when R_1 and R_2 are hydrogen, R_3 may not be *meta*- CF_3 ;

5 R_4 , R_5 , R_6 , R_7 and R_8 are, independently, hydrogen, $COOR_{15}$, halogen, nitro, cyano, C_{1-10} alkoxy, C_{1-10} haloalkoxy, sulfonic acid, C_{1-10} alkylsulfonyl, C_{6-12} arylsulfonyl, C_{6-12} aralkylsulfonyl, C_{1-10} alkylsulfinyl, C_{6-12} arylsulfinyl, C_{6-12} aralkylsulfinyl, sulfamoyl, C_{1-10} alkylsulfamido, C_{6-12} arylsulfamido, C_{1-10} alkanoyl, C_{6-12} aryloyl, C_{6-12} aralkanoyl, amino, C_{1-10} alkylamino, C_{2-10} dialkylamino, C_{6-12} aralkylamino, C_{6-12} arylamino, carboxamido, C_{1-10} alkylcarboxamido, C_{6-12} arylcarboxamido, C_{1-10} haloalkyl, C_{1-10} alkyl, C_{2-10} alkenyl, C_{6-12} aryl, and C_{6-12} aralkyl, with the proviso that at least one of R_4 and R_5 is $COOR_{15}$;

10 R_9 is hydrogen, C_{1-10} alkyl and C_{1-10} haloalkyl;

15 R_{10} is hydrogen, C_{1-10} alkyl, C_{1-10} haloalkyl, or C_{2-12} alkylidene;


10 R_{15} is hydrogen, metal cation, acetyl amido, alkoxyacetoyl or a related moiety which delivers the carboxylate in vivo;

15 the dotted line is an optional double bond; with the proviso that when R_{10} is an alkylidene moiety, the bond is absent; and

20 W is nitrogen or carbon bearing a hydrogen, or R_4 , R_5 or R_6 as hereinbefore defined; or pharmaceutical salts thereof.

30. A method for reducing the adverse effects of smooth muscle contractions which comprises administering to a patient in need thereof, a compound of the formula:

25



(I)

wherein:

- 61 -

R₁, R₂, R₃, R₄, R₅, R₆, R₇ and R₈ are, independently, hydrogen, COOR₁₅, halogen, nitro, cyano, C₁₋₁₀ alkoxy, C₁₋₁₀ haloalkoxy, sulfonic acid, C₁₋₁₀ alkylsulfonyl, C₆₋₁₂ arylsulfonyl, C₆₋₁₂ aralkylsulfonyl, C₁₋₁₀ alkylsulfinyl, C₆₋₁₂ arylsufinyl, C₆₋₁₂ aralkylsufinyl, sulfamoyl, C₁₋₁₀ alkylsulfamido, C₆₋₁₂ arylsulfamido, C₁₋₁₀ alkanoyl, C₆₋₁₂ aryloyl, C₆₋₁₂ aralkanoyl, amino, C₁₋₁₀ alkylamino, C₂₋₁₀ dialkylamino, C₆₋₁₂ aralkylamino, C₆₋₁₂ arylamino, carboxamido, C₁-C₁₀ alkylcarboxamido, C₆₋₁₂ arylcarboxamido, C₁₋₁₀ haloalkyl, C₁₋₁₀ alkyl, C₂₋₁₂ alkenyl, C₆₋₁₂ aryl, C₆₋₁₂ aralkyl; with the proviso that at least one of R₄ and R₅ is COOR₁₉;

5 R₉ is hydrogen, C₁₋₁₀ alkyl and C₁₋₁₀ haloalkyl;

R₁₀ is hydrogen, C₁₋₁₀ alkyl, C₁₋₁₀ haloalkyl, or C₂-C₁₂ alkylidene;

R₁₅ is hydrogen, metal cation, acetyl amido, alkoxyacetoyl or a related moiety which delivers the carboxylate in vivo;

10 the dotted line is an optional double bond; with the proviso that when R₁₀ is an alkylidene moiety, the bond is absent; and

15 W is nitrogen or carbon bearing a hydrogen, or R₄, R₅ or R₆ as hereinbefore defined, or pharmaceutical salts thereof.

20 31. The method of Claim 1 in which the smooth muscle adversely contracting causes urinary incontinence.

32. The method of Claim 1 in which the smooth muscle adversely contracting causes irritable bowel syndrome.

25 33. The method of Claim 1 in which the smooth muscle adversely contracting causes asthma.


34. The method of Claim 1 in which the smooth muscle adversely contracting is associated with congestive heart failure, hypertension, angina, and cardiac arrhythmias.

30 35. The method of Claim 1 in which the smooth muscle adversely contracting is associated with cerebral vascular disease.

- 62 -

36. A method of activating potassium channels in smooth muscle cells of a patient suffering from a condition associated with insufficient potassium channel activity comprising administering to a patient in need thereof a compound of formula (I):

5



(I)

10

wherein:

15

R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 and R_8 are, independently, hydrogen, $COOR_{15}$, halogen, nitro, cyano, C_{1-10} alkoxy, C_{1-10} haloalkoxy, sulfonic acid, C_{1-10} alkylsulfonyl, C_{6-12} arylsulfonyl, C_{6-12} aralkylsulfonyl, C_{1-10} alkylsulfinyl, C_{6-12} arylsulfinyl, C_{6-12} aralkylsulfinyl, sulfamoyl, C_{1-10} alkylsulfamido, C_{6-12} arylsulfamido, C_{1-10} alkanoyl, C_{6-12} aryloyl, C_{6-12} aralkanoyl, amino, C_{1-10} alkylamino, C_{2-10} dialkylamino, C_{6-12} aralkylamino, C_{6-12} arylamino, carboxamido, C_{1-10} alkylcarboxamido, C_{6-12} arylcarboxamido, C_{1-10} haloalkyl, C_{1-10} alkyl, C_{2-12} alkenyl, C_{6-12} aryl, C_{6-12} aralkyl; with the proviso that at least one of R_4 and R_5 is $COOR_{15}$;

20

R_9 is hydrogen, C_{1-10} alkyl and C_{1-10} haloalkyl;

R_{10} is hydrogen, C_{1-10} alkyl, C_{1-10} haloalkyl, or C_{2-12} alkylidene;

R_{15} is hydrogen, metal cation, acetyl amido, alkoxyacetoyl or a related moiety which delivers the carboxylate in vivo;

25


the dotted line is an optional double bond; with the proviso that when R_{10} is an alkylidene moiety, the double bond is absent; and

W is nitrogen or carbon bearing a hydrogen, or R_4 , R_5 or R_6 as hereinbefore defined; or pharmaceutical salts thereof.

- 63 -

37. The method of claim 36 wherein the patient is suffering from anxiety, cerebral anoxia or a neurodegenerative disorder.

38. A method of achieving chloride channel blockade in smooth muscle cells of a patient suffering from a condition associated with undesired chloride channel activity comprising treating the patient with a therapeutically effective amount of a compound of formula (I):



10

(I)

wherein:

15 $R_1, R_2, R_3, R_4, R_5, R_6, R_7$ and R_8 are, independently, hydrogen, $COOR_{15}$, halogen, nitro, cyano, C_{1-10} alkoxy, C_{1-10} haloalkoxy, sulfonic acid, C_{1-10} alkylsulfonyl, C_{6-12} arylsulfonyl, C_{6-12} aralkylsulfonyl, C_{1-10} alkylsulfinyl, C_{6-12} arylsulfinyl, C_{6-12} aralkylsulfinyl, sulfamoyl, C_{1-10} alkylsulfamido, C_{6-12} arylsulfamido, C_{1-10} alkanoyl, C_{6-12} aryloyl, C_{6-12} aralkanoyl, amino, C_{1-10} alkylamino, C_{2-10} dialkylamino, C_{6-12} aralkylamino, C_{6-12} arylamino, carboxamido, C_{1-10} alkylcarboxamido, C_{6-12} arylcarboxamido, C_{1-10} haloalkyl, C_{1-10} alkyl, C_{2-12} alkenyl, C_{6-12} aryl, C_{6-12} aralkyl; with the proviso that at least one of R_4 and R_5 is $COOR_{15}$;

20 R_9 is hydrogen, C_{1-10} alkyl and C_{1-10} haloalkyl;

25 R_{10} is hydrogen, C_{1-10} alkyl, C_{1-10} haloalkyl, or C_{2-12} alkylidene;

30 R_{15} is hydrogen, metal cation, acetyl amido, alkoxyacetoyl or a related moiety which delivers the carboxylate in vivo; the dotted line is an optional double bond; with the proviso that when R_{10} is an alkylidene moiety, the double bond is absent; and

35 W is nitrogen or carbon bearing a hydrogen, or R_4 , R_5 or R_6 as hereinbefore defined; or pharmaceutical salts thereof.

- 64 -

39. The method of Claim 38 wherein the condition is urinary incontinence, irritable bladder disease/irritable bowel disease, asthma, hypertension, stroke, congestive heart disease, angina or cardiac arrhythmias.

1 / 2

Figure 1.




Figure 1A




Figure 1B




Figure 1C

2 / 2

Figure 2.

Figure 2A




Figure 2B





Figure 2C



INTERNATIONAL SEARCH REPORT

Inte. onal Application No

PCT/US 98/16099

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C07C233/55 C07D213/79

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07C C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 22807 A (NEUROSEARCH AS ; OLESEN SOEREN PETER (DK); MOLDT PETER (DK); PEDERS) 13 October 1994 see claims ---	1-39
A	EP 0 524 781 A (ICI PLC) 27 January 1993 see claims ---	1-39
A	PATENT ABSTRACTS OF JAPAN vol. 009, no. 241 (C-306), 27 September 1985 & JP 60 097946 A (ONO YAKUHIN KOGYO KK), 31 May 1985 see abstract ---	1 -/-



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search:

11 November 1998

Date of mailing of the international search report

18/11/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Pauwels, G

INTERNATIONAL SEARCH REPORTInte ~~onal~~ Application No
PCT/US 98/16099**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PATENT ABSTRACTS OF JAPAN vol. 008, no. 172 (C-237), 9 August 1984 & JP 59 070654 A (NIHON REDARII KK), 21 April 1984 cited in the application see abstract -----	1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/ 16099

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 31-38
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 31-38
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking(Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte onal Application No

PCT/US 98/16099

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9422807	A 13-10-1994	AU 683654	B	20-11-1997
		AU 6537894	A	24-10-1994
		CA 2160128	A	13-10-1994
		EP 0693053	A	24-01-1996
		FI 954746	A	17-11-1995
		JP 8510448	T	05-11-1996
		NO 953956	A	07-12-1995
		NZ 265052	A	19-12-1997
		US 5696138	A	09-12-1997
EP 0524781	A 27-01-1993	AT 136027	T	15-04-1996
		AU 648423	B	21-04-1994
		AU 2047692	A	28-01-1993
		CA 2074605	A	26-01-1993
		CN 1069727	A, B	10-03-1993
		CZ 282503	B	16-07-1997
		DE 69209395	D	02-05-1996
		DE 69209395	T	17-10-1996
		DK 524781	T	12-08-1996
		ES 2084944	T	16-05-1996
		FI 923379	A	26-01-1993
		GR 3019446	T	30-06-1996
		HU 213605	B	28-08-1997
		HU 9500228	A	28-08-1995
		IE 72507	B	23-04-1997
		IL 102626	A	05-12-1996
		JP 5286915	A	02-11-1993
		MX 9204355	A	01-04-1993
		NO 178300	B	20-11-1995
		NZ 243686	A	27-04-1995
		PL 171933	B	31-07-1997
		PL 171991	B	31-07-1997
		SG 48002	A	17-04-1998
		SK 234292	A	08-03-1995
		RU 2074173	C	27-02-1997
		US 5382598	A	17-01-1995
		US 5474999	A	12-12-1995
		US 5565477	A	15-10-1996
		US 5567735	A	22-10-1996
		US 5565465	A	15-10-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Appl. No.

PCT/US 98/16099

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0524781 A		US 5684198 A US 5272163 A	04-11-1997 21-12-1993

